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ABSTRACT 
 
Background 
Considering the high number of new cases of cervical cancer each year caused by human 
papilloma viruses (HPVs), the development of an effective vaccine for the prevention and 
therapy of HPV-associated cancers, and in particular against the high-risk HPV16 
genotype, remains a priority. Vaccines expressing the E6 and E7 proteins, which are 
detectable in all HPV-positive pre-cancerous and cancer cells, might support the treatment 
of HPV-related lesions and clear already established tumors. 
 
Methods 
In this study, DNA and fowlpox virus recombinants expressing the E6F47R and E7GGG 
mutated forms of the HPV16 E6 and E7 oncoproteins were generated, and their correct 
expression verified by RT-PCR, Western blotting and immunofluorescence. The immune 
responses were determined by ELISA and ELISPOT assays and the therapeutic efficacy 
was evaluated In mice, as a pre-clinical model of HPV-16 tumorigenicity, using 
heterologous (DNA/FP) or homologous (DNA/DNA and FP/FP) prime/ boost regimens 
after challenge with syngeneic TC-1* cells. 
 
Results 
The analyses of the different recombinants showed the correct expression of the inserted 
heterologous genes. After mice immunization, while specific anti-E6 and anti-E7 humoral 
responses were just detectable, specific T-cell responses were elicited. In the therapeutic 
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protocols, after the challenge and the subsequent immunizations, a delay in cancer 
appearance was shown, thus confirming the pivotal role of the T-cell response in the 
control of tumor growth also in the absence of E6- and E7-specific antibodies. These in-
vivo experiments resulted in higher numbers of tumor-free mice after either the 
homologous or heterologous immunizations compared to the controls. 
 
Conclusions 
These data establish a preliminary indication for the prevention and treatment of HPV-
related tumors by the use of DNA and avipox constructs as safe and effective 
immunogens administered by the prime/boost strategy. The combined use of the 
recombinants expressing both the E6F47R and E7GGG proteins should improve the antitumor 
efficacy and represent an important approach to control/clear HPV-associated cancers. 
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INTRODUCTION 
 
Cervical cancer is the second most common malignancy among women worldwide [1,2] 
and approximately 500,000 new cases and 250,000 deaths are estimated each year [3].  
There are more than 100 different genotypes of this virus, 15 of which are classified as 
“high-risk” and implicated in cancers of the cervix, penis, vulva, anus, vagina and 
oropharynx [4]. The casual factor of the disease is in fact the persistent infection of some 
strains of Human Papillomavirus (HPV), mainly spread by sexual-transmission.  
HPV16 and HPV18 are the most diffused pathogenic HPVs and are associated with more 
than 70% of cervical cancers [2,5]. In particular, HPV16 is present in 50% of the tumors 
[1,2]. 
Infection restriction and prevention are difficult, since the transmission risk increases 
according to the sexual behavior, and, also by reducing the partner numbers and using the 
condom, a complete protection cannot be achieved because of the presence of infected 
cells also on the external part of the genitals [6]. 
The probability to be infected is further associated with others factors, such as smoking, 
number of sexual intercourses, age, pregnancy number, presence of other sexual 
transmitted diseases, and immunodeficiency (infection with Human Immunodeficiency 
Virus or pharmacological post-transplantation immune depression) [7].  
The viral infection can also occur by vertical transmission from the mother to the child at 
the delivery [8], and can be facilitated in subjects that ignore their infectious status, since 
the currently performed preventive screenings on the female population are suggested but 
not mandatory. 
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The screening of sexually active women that are already twenty-one year old is currently 
performed by the Papanicolau test (Pap-test). This represents a fundamental way to fight 
the spreading of cervical cancer, a malignancy characterized by a slow-progression with 
an outbreak also after years from the infection event. The Pap-test analyzes the epithelial 
tissue samples, collected from the cervix, to the aim at detecting a typical 
perinuclear/cytoplasmic vacuolization (koilocytosis) that indicates the presence of HPV 
infection. (Fig. 1) 
Unfortunately, this test is not predictive of HPV infection when the samples appear 
histologically normal, and further analyses must be performed to detect the presence of 
the viral genome. These additional analyses are generally prescribed only after a positive 
Pap-test result, so that, although these screenings are very diffused, the incidence of 
cervical cancer and the related deaths still remain high [8].  
 
 
 
 
Fig. 1.  Pap test. Micrograph showing a low grade squamous intraepithelial lesion (LSIL) 
after a Pap test. Abnormal cells have an enlarged nucleus, irregular chromatin and relatively 
abundant cytoplasm and may develop into cervical cancer. 
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The therapies currently pursued to treat the pre-cancerous lesions and the already 
developed cervical tumors involve surgery, as well as radio- and chemo-therapy. In 
general, these approaches are able to completely resolve the pathology only when the 
established Cervical Intraepithelial Neoplasia (CIN) belongs to the first or the second 
grade (CIN1 or CIN2), but they are insufficient in more severe cases of the third grade 
(CIN3) or carcinoma in situ [8]. During the last years, the scientific research was focused 
on the development of prophylactic and therapeutic vaccines able to induce both a 
humoral and cell-mediated immune response, that have been demonstrated to be involved 
in the spontaneous regression of the lesions that can occurs in some patients [6]. 
At the moment, two prophylactic vaccines against HPV are available, Gardasil® (Merck) 
and  Cervarix® (Glaxo Smith-Kline). They consist of L1capsid protein of different HPV 
strains assembled into VLPs, that are able to induce a high antibody level, and thus, 
neutralize viral infection in the vaccinated subjects. 
Both vaccines prevent 99% of infections mainly through the induction of neutralizing 
antibodies against the specific HPV types employed in the vaccine development. However, 
the induced humoral response is not sufficient to control the already established infection; 
thus, they are effective only in subjects vaccinated before the HPV transmission [9].  
Despite the current preventive vaccines, cervical cancers are still on the rise with over 
80% occurring in the poorest countries. This opens up the urgent need of developing 
therapeutic strategies targeting HPV-infected (pre)malignant cervical lesions through the 
elicitation of a cell-mediated immunity by an HPV-specific immunotherapy. The 
development of therapeutic vaccines for the treatment of cervical cancers is based on the 
possibility to induce a cell-mediated immune response targeting the early-expressed HPV 
proteins to prevent the development of new lesions and clear the already established 
ones.  
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The Human Papillomavirus (HPV) 
 
The Human Papillomavirus (HPV) belongs to the family of papillomaviridae and to the 
genus of papillomavirus. HPVs are double-stranded DNA viruses and they present a 
specific tropism for the squamous epithelial cells of the skin or of the anogenital and 
oropharyngeal mucosae. 
The viral particle (Fig. 2) has a diameter of 55 nm and an icosahedral capsid without 
envelope, which consists of the L1 and L2 structural proteins, containing a circular DNA of 
7,904 bp [4].  
 
 
 
 
 
 
 
Fig. 2.  HPV virion. Reproduction of the HPV16 viral capsid, which is characterized by 
pentameric capsomers (left panel). Electron microscopy picture of some virions (right panel).  
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The genome (Fig. 3) is expressed differently during the viral replication stages, and soon 
after infection, it appears as the episomal form, non-integrated in the genetic material of 
the host cell. HPV genome consists of 8 open reading frames, 6 early genes (E1, E2, E4, 
E5, E6, and E7), and 2 late genes (L1, and L2), the product of which vary from plain 
capsid proteins to immortalization tools, and a Long Control Region (LCR). Early genes 
are expressed in the basal, suprabasal, and intermediate cells of the cervix, during the 
initial stages of the viral cycle, and code for regulatory proteins, whereas the late genes, 
coding for the capsid proteins, are activated in the apical strata only during the final steps 
of the replication. Between the early and late regions, a regulatory Long Control Region 
(LCR) is present, which has a dimension of 1 kb and contains the origin-of-replication 
sequence.  
 
 
 
Fig. 3.  HPV genome organization. The map shows the different ORF which code for early 
and late genes. Between the early and late region the URR (Upstream Regulatory Region) is 
shown. 
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Each early protein has specific functions: E1 prepares the viral genome to be replicated by 
the host replication machinery; E2 maintains the episomal form of the viral genome and 
organizes its transcription; E5 protein modifies (when expressed) the function of growth 
factor receptors; E6 and E7 are the major oncogenic tools in the viral genome. E4 full 
potential is yet to be clarified, but its expression appears throughout the epithelium, and it 
seems to promote viral replication and disrupt the cytoskeleton in order to facilitate the 
virions escape out of the differentiated cells [10]. 
The HPV tropism is species-specific and limited to the epithelial cells, where the viral 
replication takes place at the nuclear level where the expression of the different viral genes 
is strictly related at the differentiation stages of the cells [6].  
In particular, the mature virion production occurs only in the spinous and granular most 
differentiated layers of the epithelium [11]. To allow a productive infection, the virus has to 
infect the cells of the basal epithelium, which are the only ones able to duplicate and 
provide the cells for the external layers [12]. 
After the penetration and the uncoating, that take place in the endosome, the DNA is 
released in the cytoplasm and translocated to the nucleus by the viral L2 protein. At this 
site, the transcription and duplication of the viral genome can begin, but they are still 
related to the differentiation state of the epithelium. These events occur in cells arrested in 
the G0 phase of the cell cycle, and depend on the replication machinery of the host cell, 
which is maintained active by the E6 and E7 early protein activity to allow the replication of 
the viral genome [13]. Moreover, the progression of the cell cycle is necessary during the 
first stages of the infection and for the viral gene expression [14]. Later during the viral 
replication, the L1 and L2 proteins spontaneously assemble into capsids, and the mature 
viral particles are released by desquamation of the epithelium [12] (Fig. 4). 
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HPV viruses have a distinct capability to evade the human immune system, which is 
achieved through three basic viral properties. First, immune cells cannot approach the 
virus easily since HPV has no viraemic phase. The initial infection is sited at the basal 
epithelium, whereas Langerhans cells are abundant only in the apical layers of the 
mucosa. Second, HPV does not elicit a major damage to the host cells, such as lysis, thus 
minimizing the inflammation and the subsequent signaling, and allowing the virus to 
replicate “silently” [15,16]. The third evasion mechanism is the particular gene expression 
 
 
Fig. 4.  HPV infection stages. Papillomaviruses are species-specific and tissue-specific 
viruses. HPV infects and replicates in the fully differentiating squamous epithelium only. The 
virus infectious cycle involves both temporal and spatial separation of viral protein 
expression. The virus first infects a keratinocyte in the basal layer of the epithelium. For the 
oncogenic viruses, viral gene expression is very tightly controlled during the proliferative 
phase. When the host cell stops dividing and begins to differentiate into a mature 
keratinocyte, this provides a signal to the virus to activate all of its genes to increase the viral 
genome copy number. In the case of incipient malignancy, the control of E6 and E7 
expression is lost, and gene expression in the cells becomes deregulated. In the top layers of 
the epithelium, all of the viral genes, including those encoding the L1 and L2 proteins, are 
expressed, and many thousands of viral genomes are encapsidated.  
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of the virus. The oncogene proteins in fact are kept at low levels throughout the initial life 
cycle, and the highly immunogenic products, the L1 and L2 capsid proteins, are 
synthesized only in the superficial layers of the epithelium [17,11].  
Although HPV-related tumors are infiltrated by large amounts of macrophages that 
aggregate at the infection site after the recognition of transformed cells [18], their presence 
inside the microenvironment of solid tumors can have a part in disease progression. In 
fact, tumor-associated macrophages promote cancer cell proliferation and migration, 
angiogenesis and restriction of immune defenses [19], thus resulting in the disruption of 
the basement membrane, tumor growth, and metastasis. 
During the immune response against pathogens, the balance between Th1 and Th2 must 
be sustained invariably in order to face intracellular or extracellular attacks, but this 
delicate interplay between the two phenotypes is distorted in HPV lesions. The HPV, as an 
intracellular enemy, should evoke Th1 immune response, but it appears that, in patients 
with intraepithelial and invasive cervical HPV lesions, the Th2 cytokine profile is prevalent. 
It is important to note that the reduced Th1 and increased Th2 responses lead to the 
suppression of cellular immunity and lesion progression [20,21]. 
Finally, HPV has developed defenses against cytotoxic T cells. In particular, the E7 
oncogene down-regulates the expression of an antigen peptide transporter, which has a 
pivotal role in associating the MHC class I molecule with the viral antigen, which results in 
the suppression of HPV antigens’ presentation and evasion from the human cellular 
defense [22,23]. Also the E5 protein has been found to down-regulate MHC/HLA class I 
[24]. 
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HPV16 and the neoplastic transformation  
 
HPV16 has a specific tropism for the mucosal epithelium of the anogenital and 
oropharyngeal tracts, in which it induces lesions. These lesions can spontaneously 
regress, unless the infection is persistent, and can evolve in more severe stages, leading 
to the development of carcinomas (Fig. 5). 
 
The virus induces neoplastic transformation by the over-expression of the early E6 and E7 
proteins, which are essential for the induction of the uncontrolled proliferation of the 
infected epithelial cells and lead to the malignancy [25]. The two oncogenic proteins 
cooperate in the induction of the neoplastic transformation by interacting with specific host 
cell targets involved in the regulation of the cell cycle and apoptosis [25,26].  
 
 
Fig. 5.  HPV infection and malignant development. HPV infects the basal epithelial cells 
through microtraumas in the skin. In the vegetative life cycle, the coordinated expression of 
the viral gene products (from early to late) results in genome amplification, and, ultimately, to 
the generation of new infectious virus particles. Disruption of cell polarity in the basal cells 
and the promotion of aberrant cell division can contribute to a further expansion of infected 
cells that are capable of supporting viral genome amplification. Persistent infection with HPV 
over a number of years is linked to a much higher risk of the development of cervical cancer. 
This process is accompanied by frequent viral DNA integration into the host genome and an 
up-regulation in the expression of the E6 and E7 oncoproteins, resulting in the complete loss 
of polarity control and, ultimately, in invasion and metastasis. 
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In particular, E7, a small protein that is mainly localized in the nucleus [27], binds the 
oncosuppressive cellular Retinoblastoma protein (pRb) [28]. PRb can be differently 
phosphorylated during the cell cycle: in the G0 and G1 phases it is active and hypo-
phosphorylated (pRb), whereas during the S, G2 and M phases it is hyper-phosphorylated 
(ppRb). In its active form, pRb is able to bind and inhibit the E2F/DP1transcriptional 
complex. This inactivates the binding of the complex to its promoter sequence and the 
following cell cycle progression and apoptosis are down-regulated [29]. The hyper-
phosphorylated form is inactive and unable to bind the E2F transcriptional factor, and thus 
induces the transcription of the genes involved in the DNA synthesis and in the cell cycle 
progression [30,31]. In HPV16 infected cells, E7 binds and sequestrates pRb, allowing the 
constitutive expression of the genes regulated by E2F/DP1 transcriptional complex [31].  
The HPV16 E6 oncogenic protein inhibits signals that induce the “programmed cell death”, 
which usually occurs after DNA damage or oncogene activation, and thus E6 mediates an 
anti-apoptotic activity. The most important E6 cell target is the p53 onco-suppressive 
protein, which usually regulates the expression of proteins involved in the cell cycle, such 
as the p21 cyclin-dependent kinase inhibitor, which, when expressed at high levels, 
induces cell cycle arrest and apoptosis [34]. In particular, E6 generates a trimeric complex 
with p53 and the ubiquitin protein-ligase E6AP [35]. After forming this complex, E6AP 
leads to the ubiquitination of p53 and its subsequent degradation by the 26S proteasome 
[35], which results in its drastic decrease and the consequent inhibition of its transcriptional 
functions. This mechanism determines the elimination of the check-points between the G1 
and S as well as between the G2 and M phases of the cell cycle, that are normally 
regulated by the p53 expression [36]. Moreover, E6 carries out an anti-apoptotic activity by 
inducing the degradation of p53-indipendent cellular factors, involved in the adhesion, the 
cell polarity and the negative regulation of cell proliferation, such as hDLG, hScrib, hMAGI-
16 
 
1 and MUPP1 [37,38]. E6 also induces cell immortalization by blocking the telomeres 
reduction, that normally represents an important signal for cell senescence [39,40]. 
The E6 and E7 oncoproteins have therefore a combined action: E7 increases p53 levels, 
leading to the cell cycle arrest or the apoptosis of infected cells, whereas E6, by inducing 
p53 degradation, inhibits the pro-apoptotic signals, allowing the progression of the infected 
cells in the cell cycle, and thus inducing the neoplastic transformation and immortalization 
(Fig. 6). 
 
 
Fig. 6.  Stimulation of cell-cycle progression by high-risk HPV types. HPV infection 
leads to deregulation of the cell cycle. Regulation of protein expression in uninfected 
epithelium is shown in (A). In the presence of high-risk HPV (B), the regulation of proteins 
necessary for cell proliferation is altered, allowing HPV to stimulate S-phase entry in the 
upper epithelial layers.  
In cervical epithelium infected by high-risk HPV types, the progression through the cell cycle 
is not dependent on external growth factors, but it is stimulated by the E7 protein, which 
binds and degrades pRB and facilitates E2F-mediated expression of cellular proteins 
necessary for S-phase entry.  
Cells respond to this stress by activating anti-oncogenic pathways, but these are 
counterbalanced by the E6 protein, which associates with the E6AP ubiquitin ligase in order 
to stimulate the degradation of the p53 protein and prevent growth arrest and/or apoptosis.  
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For tumor development, HPV16 must persistently infect the epithelial basal cells. When 
these cells replicate, the viral genome is distributed in both the daughter cells, which 
migrate into the granular layer where the differentiation process has begun [36]. In the 
uninfected tissue, the cells that leave the basal layer lose the nucleus and their capability 
to proceed in the cell cycle, but, thanks to E7 expression, the HPV-infected cells maintain 
their active state, proceed in the cell cycle [41] and rescue the nucleus during the 
migration along the epithelial tissue [36]. The transformed and immortalized basal cells 
generate daughter cells, which are unable to differentiate in keratinocytes, thus developing 
intraepithelial lesions of first grade (CIN1). These lesions, if not treated, can evolve in more 
severe forms (CIN2 and CIN3) with the invasion of the epithelium and the carcinoma 
development (Fig. 7). 
 
 
 
Fig. 7.  Progression of persistent human papillovmavirus (HPV) infection in the cells of 
the cervix. A progression from normal to tumor cells is shown. The nucleus-to-cytoplasm 
ratio increases as cells progress through the stages of dysplasia and cancer.  
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HPV vaccines 
 
To fight the HPV infection and the HPV-related cervical cancer, two immunization 
approaches can be pursued, a preventive strategy with the purpose of blocking the 
infection in still-healthy subjects, or a therapeutic strategy to clear the established infection 
and/or tumor already developed in infected subjects. 
The preventive vaccines currently available are based on the capability of the viral L1 
capsid protein of self-assemble in 72 pentameric capsomers, even in the absence of the 
L2 protein [42]. This event promotes the formation of empty capsids, the Virus-Like 
Particles (VLPs), which are structurally and immunologically similar to the virions, and, 
lacking the DNA genoma, completely safe [43]. 
At present, two preventive vaccines are commercialized and used globally: a quadrivalent 
HPV vaccine, produced by Merck & Co. Inc. (Gardasil®, Merck, Rahway, NJ, USA), and a 
bivalent HPV vaccine, produced by GlaxoSmithKline plc. (Cervarix™, GSK, Middlesex, 
UK). Gardasil® contains the VLPs from HPV type 6, 11, 16, and 18 and aluminum 
hydroxyphosphate sulfate as an adjuvant. Cervarix™ contains the VLPs from HPV type 16 
and 18 and the AS04
 
adjuvant, which is a combination of aluminum hydroxide and 
monophosphoryl-lipid A (MPL) [44-47]. Unfortunately, preventive vaccines cannot control 
already established HPV infections, and the long delay before tumor development limits 
the assessment of their effects in lowering HPV tumor incidence over time. Although 
extensive screening for early diagnosis has led to a reduction in the mortality of women in 
developed countries, the 500,000 new cases of cervical cancer each year make the 
development of an effective therapeutic vaccine mandatory. 
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In a therapeutic setting, immunity can be utilized in two ways: by using specific natural or 
synthetic antibodies against defined targets, or by inducing an immune response in the 
host against specific antigens. In particular, for HPV-related lesions and cancer, viral 
antigens or/and virus-induced host antigens can be targeted by the following approaches. 
 
Therapeutic antibodies 
The use of intracellular antibodies (intrabodies) to inhibit protein functions holds promise 
for the treatment of human diseases. The difficulties associated with the development of 
intrabody-based therapies are similar to those that hamper the development of protein 
inhibitors in general, and reflect the problems encountered in the generation of reagents 
that are effective and specific. 
For viruses that cause only local infections, such as HPV, the intrabody approach may be 
more appropriate. Intrabodies against E6 [48] and E7 [49] have been produced and proved 
to be effective in in vitro cancer cell models. More recently, an intrabody approach against 
E7 was proved to block tumor growth in animal models [50]. Given the accessibility of 
HPV-associated lesions to topical therapy, preclinical data suggest that large molecules, 
such as intrabodies, may be useful inhibitors of viral protein–protein interactions and 
particularly appropriate for the treatment of HPV-associated diseases. 
 
Therapeutic vaccines 
Therapeutic vaccines aim at eradicating or reducing HPV-infected cells by stimulating a 
specific cytotoxic T cell (CTL) response against infected target cells through the up-
regulation of MHC Class I expression. Vaccine-mediated immune strategies could be 
directed towards at least two different stages: the viral infection and the established tumor. 
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Therapeutic vaccines should be able to eliminate the already-infected cells, and could be 
tailored on the presence of episomal or integrated viral sequences. In the first case, the 
vaccine targets could be all the early proteins, in the second case only E6 and E7 appear 
to be the realistic targets of intervention [51]. To this aim, the E6 and E7 of high-risk HPV 
genotypes could represent a good target for the immunotherapy, since they are expressed 
in 90-95% of cervical tumors and they are responsible for the cell transformation and 
progression of pre-neoplastic lesions to neoplasias [50,52].  
 
Protein/peptide-based vaccines 
To date, several protein or peptide-based vaccines are in development or undergoing 
clinical evaluation. A major limitation to peptide-based vaccines is the HLA restriction that 
can be overcome by the use of whole-protein-based vaccines harboring multiple 
immunogenic epitopes that can bind various allelic HLA molecules. On the other hand, 
protein-based vaccines predominantly elicits antibody rather than CTL responses, as 
proteins are processed intracellularly through the endocytic/MHC class II pathway. In 
addition, peptides and proteins administered without an adjuvant are poorly immunogenic. 
Therefore, most researches were focused on immunogens co-expressing chemokines, 
cytokines, and co-stimulatory molecules or co-administered with saponin-based [53] or 
liposome–based (LPD) formulations [54] and TLR agonists [55] as adjuvants to enhance 
vaccine potency. Peptide-based vaccines need to increase not only their low level of 
immunogenicity but also the obstacle of MHC restriction. To this aim TLR agonists have 
been explored as adjuvants for peptide-based HPV vaccines because of their capability to 
activate both innate and adaptive immunity and vaccines consisting in CTL and or TH 
epitopes, adjuvanted with TLR9 [56], TLR4 [57] and TLR3 [58] agonists, demonstrated 
their efficacy in mouse models. 
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DNA based genetic vaccines 
Although DNA expression plasmid vaccines do not appear to induce as vigorous immune 
responses as live viral vaccine vectors, they have several advantages. Mainly, naked DNA 
is relatively safe, stable, cost efficient, and able to sustain reasonable levels of antigen 
expression within cells. Many strategies have been employed to produce an efficient 
delivery of targeted antigen to antigen-presenting cells (APC) such as dendritic cells 
(DCs), an enhancement of antigen processing and presentation, and an increase of DC 
and T cell interaction [59]. Recently, it has been reported that the fusion of the E7 gene of 
HPV16 with a plant virus coat protein produced a strong antitumor activity in the mouse 
model by activating both CD4+ and CD8+ T cells [60,61]. Similar results were obtained by 
fusion of the E7 gene to a gene encoding the mutated form of the immunotoxin from 
saponaria officinalis, the saporine [62]. Two different phase I clinical trials, examining the 
potential treatment of patients with anal dysplasia or with high-grade CIN, showed 
promising immunological responses [63,64]. An improved version of the vaccine, that 
includes HPV16 E7 and gene segments of E6 and E7 of HPV16/HPV18, is one of the few 
therapeutic vaccines reaching the phase II/III clinical trials in subjects with high-grade CIN. 
In a prospectively defined population of women younger than 25 years, CIN resolution was 
significantly higher in the vaccinated groups compared to placebo [65]. 
 
Bacterial/viral vectors 
Bacteria, such as Listeria monocytogenes (LM) [66,67], Lactococcus lactis [68], 
Lactobacillus casei [69], Salmonella and Bacillus Calmette-Guérin, and several viral 
vectors, including Vaccinia Virus (VV), adenovirus, adeno-associated virus, alpha-virus, 
and their derivative vectors, have been used to deliver genes or proteins of interest to elicit 
antigen-specific immunotherapy. Among the bacterial vectors, LM has emerged as a 
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promising vector, as it is able to induce both CD8+ and CD4+ T-cell immune responses in 
animal models, to elicit regression of established tumors, and to overcome central 
tolerance by expanding low avidity E7-specific CD8+ T cells [66]. Among viral vectors 
engineered for the expression of HPV antigens, like adenoviruses [70,71], alpha-viruses 
[72-74] and VV [75-77], which was historically one of the first viral vectors employed in 
clinical trials in the therapy against HPV-associated cancers [78]. More recently, avipox 
viruses have been developed as novel vectors for the development of recombinant 
vaccines. Avipox viruses as canarypox (CP) and fowlpox (FP) might therefore represent 
safer immunogens, as they have demonstrated their activity in inhibiting the growth of 
HPV16 E7-expressing tumors in C57Bl/6 mice following a DNA-prime/fowlpox boost 
immunization protocol [79].  
To date, many VV vaccines have been employed in clinical trials to deliver genes and 
antigens of interest efficiently. Phase I/II clinical trials in patients with vulvar or vaginal and 
early- or late-stage cervical cancers were already conducted with recombinant VVs 
encoding HPV16/HPV18 E6 and E7 antigens (TA-HPV) [78,80-82]. 
 
DC-based vaccines 
The immune response to the initial stages of infection causes inflammatory responses that 
trigger innate effector cells, such as NK and NKT cells. This inflammatory response drives 
the innate immunity. The non-lytic nature of HPV infection also delays PAMP- and DAMP-
induced inflammatory responses through TLRs and the inflammasomes. In the absence of 
inflammation, a number of events takes place that induce negative regulatory signals that 
can change the state of APCs by altering the expression of co-stimulatory molecules, and 
inhibit the induction of effector cytotoxic T cells. Therefore, a therapy aimed at reactivating 
these APCs could be a valid tool for clinical intervention. 
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Combinational immunotherapy 
Given the importance of local microenvironment in the persistence of HPV lesions, 
strategies aiming at altering local immunity have shown some positive results. Therefore 
therapeutic HPV vaccine strategies have shifted toward combined approaches with 
radiotherapy and chemotherapy. Low-dose radiation in combination with HPV vaccination 
was effective in the treatment of tumors in preclinical models [83]. In particular, a 
chemotherapeutic agent in combination with DNA-based vaccines was proven as an 
effective HPV therapy in preclinical models [84-90]. 
 
Non-oncogenic E6F47R and E7GGG mutated proteins 
 
Several studies suggest that E6 and E7 oncoproteins of high-risk HPVs are favorable 
targets to limit and inhibit the proliferation of cervical cancer cells due to their sustained 
expression in cancer tissues and their involvement in malignant transformation. The E6 
inhibition was obtained either by decreasing the mRNA levels by RNA interference [91] or 
by transducing anti-E6 antibodies [92] or recombinant antibody fragments [48]. E6 
mutants, defective for their binding to the p53 cellular target protein, have induced high 
levels of the oncosuppressor protein when introduced into HPV-positive cancer cells and 
senescence in HeLa cells [93], with a subsequent cell cycle arrest, sometimes leading to 
apoptosis.  
E6F47R is a genetically mutated form of the HPV16 E6 protein, defective in its ability to lead 
the degradation of p53, because of the presence of a single-site mutation that determines 
the substitution of the phenylalanine in position 47 (F47) with an arginine (R) [94]. This 
mutation was introduced in a previous mutant, called E6 6C/6S, in which six cysteine 
residues were substituted with six serine to overcome problems related to the oxidation 
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and formation of aggregates that were shown during the HPV16 E6 recombinant protein 
production [95]. This mutant precursor, which maintained the oncogenic activity of the wild-
type E6 protein, was modified to substitute different surface residues with the aim at 
verifying their effect on p53 degradation. The F47R mutation was the only substitution 
which showed to be able to inactivate the p53 degradation both on rabbit reticulocyte 
extracts, and on HPV-positive or -negative cells. Moreover, it was demonstrated that HeLa 
cells , which are derived from cervical cancer and constitutively express the HPV18 E6 
protein, when transfected with E6F47R showed an increase in the levels of their 
endogenous p53 [94].  
However, the native E6 protein presents the F47 amino acid residue completely exposed 
on the surface, and thus this mutation should not induce any change in the protein folding, 
although the presence of a positive charge on the introduced arginine generates 
electrostatic effects that alter the catalytic activity of the complex. E6F47R maintains the 
affinity for the ubiquitin ligase E6AP, and its ability to form the trimeric complex 
E6F47R/E6AP/p53, but it lacks the capacity to induce the p53 polyubiquitination and  
degradation. The mutant protein is also able to have a negative dominant effect on the 
native E6 protein and is able to degrade the p53 in vitro as well as in vivo. In fact, in CaSki 
and SiHa cells, both HPV16-positive cell lines, the mutant protein can reactivate the p53 
expression by a competitive mechanism against the endogenous native E6. When E6F47R 
is overexpressed, the E6F47R/E6AP/p53 complex forms prevalently, instead of the complex 
with the E6 wild-type protein, leading to a reduction of the p53 degradation. The complex 
with the mutant protein also shows an increased half-life compared with the wild-type 
complex. Thus, the E6F47R prevents the cell growth and induces senescence in HPV-
positive cells counteracting the oncogenic activity of the original E6 protein and behaving 
as an oncosuppressor [93]. 
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The E7GGG protein is a mutant form of the HPV16 E7 oncoprotein, which was obtained by 
the introduction in the E7 gene of three single-site mutations in a region that represents 
the binding site to the target pRb oncosuppressor protein. These mutations induce the 
substitution of aspartate, lysine and glutamate amino acids with three glycine residues 
(GGG) in position 21, 24 and 26, respectively [96]. Each of these mutations can decrease 
or completely abolish the binding to the cellular pRb target protein, and the oncogenicity of 
native-E7. Moreover, it has been demonstrated that the E7 mutation inside the binding site 
significantly increases the immunogenicity of the protein [96]. In fact, the native protein 
suppresses the capacity to present the antigen by inhibiting DC differentiation [97], 
whereas E7GGG lacks this property and the antigen presentation is enhanced. 
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Poxviruses 
 
Structure and replication 
Poxviridae is a family of DNA viruses able to infect both vertebrates (subfamily 
Chordopoxvirinae) and invertebrates (subfamily Entomopoxviridae). Poxviruses are big 
sized (360 x 270 x 250 nm), ovoid and brick-shaped (Fig. 8) with some differences 
depending on the genus, and a more complex morphology than the other viruses. 
The external structure consists of an envelope with a double-lipid layer membrane where 8 
polypeptides are inserted. In the mature extracellular form, an additional outer membrane 
is usually present, which is absent in the intracellular forms and in the extracellular 
particles released by cell lysis. The envelope surrounds a dumbbell-shaped core, also 
called nucleoid, that consists of nucleoproteins with two associated structures, called 
lateral bodies, containing enzymes.  
 
 
 
Fig. 8.  Poxvirus virions. Schematic representation of the two distinct infectious viral particles: 
Intracellular Mature Virion (IMV or MV) and Extracellular Enveloped Virion (EEV or EV) 
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The poxvirus genome consists of a linear double-stranded DNA, with close ends, and a 
dimension comprised between 8.5 x 107 and 1.85 x 108 Da from parapoxviruses to 
fowlpoxviruses, respectively. The genome has a central region containing highly 
conserved genes involved in the viral replication, which can be distinguished in early, 
intermediate and late genes, on the basis of their activation during the viral replication. The 
two lateral regions include variable genes involved in the interaction with the host, and two 
Inverted Terminal Repetitions (ITRs) which consist of subsequent and repetitive, inverted 
sequences. Finally, two loops, called hairpin loops, link the two DNA lateral chains and are 
involved in the synthesis and desegregation of the DNA concatemer, that are transiently 
formed during the replication [98]. The viral particles contain enzymes for the DNA 
transcription and maturation (capping, polyadenylation and methylation). 
Two different viral forms are able to infect the cell, the Intracellular Mature Virion (MV) and 
the Extracellular Enveloped Virion (EV), which has an additional outer membrane that is 
absent both in the MV and the extracellular virions released by cell lysis [99].  
 
The poxvirus replication consists of several stages (Fig. 9) and begins with the binding to a 
cellular receptor on the host cell surface and the subsequent penetration and uncoating. 
The MV penetration occurs by fusion with the cytoplasmic membrane, whereas EV enter 
by endocytosis and fusion with the endosome membrane [100]. The following events 
include early genes transcription, DNA replication, late genes transcription, structural 
protein synthesis, maturation, assembly and release of the new viral progeny. During 
these stages, proteins coded in the previous step are required for the regulation of the 
genes that will be expressed during the following stage. Immediately after the infection, the 
viral mRNA transcription and maturation by capping, methylation and polyadenylation 
occurs inside the host cell. The early genes code for proteins that are expressed before 
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the DNA replication, whereas the late genes, coding for core and structural proteins and 
enzymes that will be included in the mature virions, are expressed after the replication of 
DNA. Finally, mature virions are released from the cell by exocytosis and cell lysis. 
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Fig. 9.  Poxvirus replication. During the viral replication, both MV and EV can enter the cell 
by binding and fusion with the cell plasma membrane. After the viral uncoating, early genes 
are expressed that support viral DNA replication and modulate cellular functions. Products of 
intermediate genes tend to modulate intracellular functions. At the later stage, late gene 
products are produced to induce viral particles assembling. After assembling in the factories, 
virions are released from the host cell by lysis or exocytosis. 
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Fowlpox virus as a vaccine vector 
The FP virus belongs to the family of Poxviridae and to the genus of Avipoxvirus, and, in 
its attenuated form, is used to prevent the corresponding poxvirus pathology in the poultry. 
The FP genome is a double-stranded DNA of 288 kbp, containing around 260 genes, and 
consists of a central region sided by two Inverted Terminal Repeats that have 
transcriptional promoter functions [101] (Fig.10).  
 
 
 
Different promoter sequences are involved in the regulation of proteins expression during 
the early and late stages of the viral replication.  
Like the other poxviruses, the FP virus has a unique transcriptional element that is 
recognized by the viral RNA polymerase. After specific deletions, its genome dimension 
allows the insertion of several exogenous genes, and, if the insertion occurs inside non-
essential genes, its replicative ability is maintained. As a poxvirus, FP exclusively 
replicates in the cytoplasm, thus limiting the recombination events between the viral and 
host cell genomes, and the safety concerns shown by the other viral vectors used for 
 
 
Fig. 10.  Fowlpox virus genome. The genome of the fowlpox virus consists of a double-
stranded and linear DNA, flanked by inverted terminal repeat (ITR) sequences, which are 
covalently-closed at their extremities. 
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vaccine development. In particular, the FP virus, as well as the CP virus, although able to 
infect non-avian hosts, show an abortive replication in mammalian cells [102]. For these 
reasons, when used as a vector, the FP virus behaves as a live-attenuated vaccine 
capable to express the foreign genes and allows a proper processing of the antigens, that 
are presented in their native conformation in association with both class I and class II MHC 
molecules [103,104].  
 
Some research groups have developed FP recombinants, that have demonstrated to 
express heterologous viral antigens, such as the 67 kDa glycoprotein of the Rabies Virus 
[105,106] and different proteins of the Human Immunodeficiency Virus [103,104,107-109].  
Since the immunization with FP recombinants elicit very low levels of immune responses 
to the vector, it is possible to perform multiple boosts, and thus enhance the protective 
efficiency [110,111]. Moreover, the FP virus does not immunologically cross-react with the 
vaccinia virus, and can thus be administered also in subjects previously vaccinated against 
smallpox [112]. The abortive replication in mammal cells, its low pathogenicity and its 
ability to synthesize the antigens for a long time (up to 3-4 weeks) [113] allow a safe and 
continuous stimulation of the immune system [114], able to induce both an innate immune 
response, by activating natural killers cells and macrophages, and a specific immune 
response, by inducing B and T lymphocytes [115]. Finally, the FP genome size allows the 
insertion of multiple genes with a dimension up to 25 kbp [116-118], thus permitting the 
use of a unique recombinant vector against different pathogens. Not last, the genetic 
stability, the low-cost of production and the safety of this virus represent important features 
that enable FP to be used as an optimal vector for the production of Virus Like Particles 
(VLPs), expressing proteins in their native conformation.  
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AIM OF THE STUDY 
 
The cervical cancer is one of the most important causes of morbidity and mortality in 
women worldwide, with a high prevalence in developing countries, where the screening for 
the precancerous lesions are not so much diffused. 
The development of vaccines represents an improvement for the prevention of the 
disease, but the high numbers of newly infected subjects occurring each year, the 
impossibility to vaccinate already infected subjects as well as the difficulty to assess the 
duration of the vaccine protection, still represent a problem. 
During the last years, research efforts have been focused on the development of 
therapeutic vaccines to treat already established HPV-induced precancerous lesions and 
carcinomas. 
The aim of this project has been the construction and evaluation of two novel FP-based 
viral recombinants able to express a mutated, non-oncogenic, form of the E6 and E7 
proteins of HPV16. 
To this purpose, the E6F47R and E7GGG genes were separately inserted into DNA 
expression plasmids as well as into recombination plasmids with the aim of generating 
viral FP recombinants by a site-specific in vitro recombination in permissive CEFs. The 
viral recombinants were then selected by plaque purification, amplified and analyzed to 
assess their ability to express correctly the heterologous genes in different cell lines. 
Finally, genetic and viral recombinants were involved in mice immunization by prime/boost 
protocols to evaluate their capability to stimulate specific immune responses, and 
therapeutic efficacy against already established HPV-induced tumors in the mouse model. 
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MATERIALS AND METHODS 
 
Cell lines 
 
CEF  
Specific-pathogen-free primary Chick Embryo Fibroblasts (CEFs) were used for the 
production and titration of the FP wild-type virus (FPwt) and the viral recombinants 
(FPE6F47R and FPE7GGG) as well as for the evaluation by RT-PCR, Western blotting and 
immunofluorescence, the expression of the E6F47R and the E7GGG proteins. CEFs were 
grown in Dulbecco’s Modified Essential Medium (DMEM, Gibco, Life Technologies, 
Rockville, MD) supplemented with 5% heat-inactivated calf serum (CS, Gibco), 5% 
Triptose Phosphate Broth (Difco Laboratories, Beckton Dickinson, NJ), and 100 U/mL 
penicillin and 100 mg/mL streptomycin (P/S, Sigma Aldrich, Milan, Italy). 
CEFs were prepared using specific-pathogen-free 11 day olds chicken eggs. Briefly, after 
disinfection with iodate-alcohol and incision of the eggshell, the embryo was extracted and 
the head and internal differentiated organs were removed. The remaining tissues were 
washed with Phosphate Buffered Saline calcium and magnesium-free (PBS-), and then 
mechanically fragmented. After sedimentation, the fragments were washed three times 
with PBS-, and dissociated by enzymatic digestion by adding one volume of 0.25% trypsin 
(Sigma) in PBS- and gently stirring at 37 °C for 15 min. The digestion was blocked by 
incubating at 4 °C for 5 min, and the supernatant was filtered through sterile gauze. The 
cell sediment was repeatedly digested enzymatically until the complete disaggregation of 
the tissues occurred. The cell suspension was then diluted with an equal volume of growth 
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medium, and centrifuged at 2,800 x g for 15 min. After removal of the supernatant, the cell 
pellet was resuspended in growth medium and cells were distributed in Petri dishes.  
 
Vero and MRC-5 
Green monkey kidney (Vero) cells and normal human lung fibroblasts (MRC-5) were used 
to detect the expression of E6F47R and E7GGG proteins by the FPE6F47R and FPE7GGG 
recombinants in RT-PCR, Western blotting and immunofluorescence assays. Vero cells 
were grown in DMEM supplemented with 10% CS and P/S, whereas MRC-5 cells were 
grown in DMEM supplemented with 10% heat-inactivated fetal calf serum (FCS, Gibco) 
and P/S. 
 
CaSki 
CaSki cells, which contain multiple copies of the integrated HPV16 genome, were used as 
a positive control for E6/E7 protein expression, whereas the CaSki lysates were used as 
plate-bound antigens for ELISA assays. CaSki cells were grown in DMEM supplemented 
with 10% CS and P/S. 
 
TC-1* 
TC-1 star (TC-1*) mouse cells, which constitutively express the HPV16 E6 and E7 
oncoproteins, and are able to induce tumors in 100% of mice [60], were used to induce 
tumors in the vaccinated animals. TC-1* cells were kindly provided by T.C. Wu (J. Hopkins 
Med. Ins., Baltimore, MD) and were grown in DMEM supplemented with 10% CS and P/S. 
 
All of the cells have been maintained at 37 °C with 95% relative humidity and 5% CO2. 
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Plasmids 
 
pQE30-E6-His and pQE30-E7-His 
To produce the E6 and E7 proteins, which were used as controls, plasmids pQE30-E6-His 
and pQE30-E7-His, kindly provided by Dr. Giorgi (Istituto Superiore di Sanità, ISS, Roma, 
Italy) and containing the HPV16 E6 and E7 genes, were inserted into E. Coli JM109 
competent bacteria. 
The transformation of the competent bacteria was performed by heat shock. Briefly, to the 
bacterial suspension were added 50 μg of plasmid, incubated on ice for 30 min, 
transferred at 42 °C for 40 sec and again on ice for 2 min. Bacteria were then added of 
450 μL of Luria-Bertani broth medium (LB, 1% Bacto Triptone, 0.5% Bacto Yeast Extract, 
0.172 M NaCl) and incubated at 37 °C for 1 h. After determining the plasmid presence, 
one bacterial clone was grown and stored at -80 °C.  
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pFP 
The pFP recombination plasmid (Fig. 11) contains a sequence derived from pUC19, and 
two segments of the 3- β-hydroxysteroid dehydrogenase-steroid isomerase (DH) gene, 
that allow the homologous recombination with the FPwt genome during the in-vitro 
recombination (IVR). The sequence of the VVH6 poxviral early-late promoter is also 
present between the two DH recombination arms, which determines the constitutive 
expression of the inserted gene, followed by a multicloning site (MCS) for the insertion of 
the exogenous gene of interest. 
 
 
 
 
 
 
 
 
Fig. 11.  Map of pFP recombination plasmid  
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pFPE6F47R 
The pFPE6F47R recombination plasmid (Fig. 12) was generated from pFP by insertion of the 
E6F47R gene down-stream of the VVH6 promoter. E6F47R gene was kindly provided by G. 
Travé (CNRS, University of Strasbourg, Illkirch, France). This mutant was obtained by 
replacing one phenylalanine (F) with one arginine residue (R), and six cysteine (C) with six 
serine (S) residues. The first mutation prevents the p53 degradation, and thus the 
oncogenic activity of the native E6 protein, whereas the C/S substitutions were introduced 
to minimize oxidation and stabilize the protein.  
 
 
 
 
 
 
 
 
 
Fig. 12.  Map of the pFPE6F47R recombination plasmid 
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pFPE6F47R construction 
 
Amplification of the E6F47R insert 
The E6F47R gene was amplified by PCR using pSG5-E6F47R as a template, the forward 
V364 (5’ ccg cgc ccg gga agc tta tgc acc aaa aga gaa ct 3’) and the reverse V99 (5’ cga 
agc ttt tac agc tgg gtt tct cta cg 3’) primers. The primers were designed to be 
complementary to the terminal sequences of the E6F47R gene, and to generate at the end 
sides two sequences containing restriction sites for the subsequent insertion of the 
heterologous gene into the vector. The PCR reaction was performed with 1 mM MgCl2, 
200 μM dNTPs, 1 μM primers and 0.025 U/μL Pwo polymerase (Boehringer Mannheim, 
Indianapolis, IN) in MgSO4 buffer. The amplification was conducted using a Thermo Cycler 
PTC-200 (MJ Research, Walthman, MA) by initial denaturation at 94 °C for 1 min, followed 
by 30 cycles of 94 °C for 30 sec, 60 °C for 30 sec and 72 °C for 30 sec, and one final cycle 
at 72 °C for 7 min. 
 
Subcloning of E6F47R in an intermediate vector  
The E6F47R gene was first inserted in an intermediate pCR-BluntII-TOPO plasmid 
(Invitrogen, Carlsbad, CA) using the PCR-amplified sequence. The ligation was performed 
for 30 min, and was followed by bacterial transformation using the Zero Blunt TOPO PCR 
Cloning Kit (Invitrogen). This last plasmid, which has blunt ends bound to the Vaccinia 
Virus topoisomerase I, has allowed an easy insertion of the DNA fragment into the 
intermediate vector. 
The bacterial suspension was seeded on Petri dishes containing LB agar in the presence 
of kanamycin (50 μg/mL) and incubated at 37 °C overnight (o/n). Some bacterial clones 
were transferred for 1 h in 1 mL of LB for a PCR pre-screening, with the aim at verifying 
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the presence of the insert, by using the forward V226 (5’ gta aaa cga cgg cca g 3’) and 
reverse V227 (5’ cag gaa aca gct atg ac 3’) primers, which are complementary with the 
plasmid vector. After initial denaturation at 94 °C for 4 min, the amplification was 
performed by 35 cycles at 94 °C for 30 sec, 50 °C for 30 sec and 72 °C for 45 sec, and 
one final cycle at 72 °C for 7 min. PCR-positive clones were added of 1 mL LB, incubated 
at 37 °C o/n, and the plasmid DNA was extracted by the minilysates method. Briefly, the 
bacterial suspension of each clone was centrifuged at 25,000 x g for 1 min, and, after 
removing the supernatant, the pellet was resuspended in 200 μL of cold buffer (50 mM Tris 
HCl, 10 mM EDTA, pH 8). The suspension was added of 200 μL of lysis buffer (200 mM 
NaOH and 1% SDS) and incubated at room temperature for 10 min. Then, 200 μL of 
CH3COOK 3 M (pH 4.8) were added to precipitate the cell debris, and the mix was 
incubated at 4 °C for 5 min. After centrifugation at 16,000 x g and incubation at 4 °C for 10 
min, the supernatant, containing the plasmid DNA, was added of 1 mL of 100% EtOH. A 
further incubation was then performed at room temperature for 10 min, followed by a 
centrifugation at 25,000 x g and 10 min at 4°C. The precipitated DNA was washed with 
500 μL of 70% EtOH, dehydrated and resuspended in bidistilled water. 
The presence of the insert was confirmed by digesting enzymatically the plasmid DNA with 
HindIII (Fermentas, M-Medical, Milan) and EcoRI (Fermentas) using 4 U/μg of DNA, and 
incubating at 37 °C for 1 h. The obtained fragments were separated by electrophoresis on 
0.8% agarose gel. Finally, one positive plasmid clone was chosen and sequenced 
(Genenco, M-Medical, Milan) to verify the absence of any mutations, which could be 
introduced into the sequence after PCR amplification. The plasmid, called pCR-BluntII-
TOPO/E6F47R, was amplified, purified by the mini extraction kit (Qiagen, Hilden, Germany), 
and used for cloning.  
 
40 
 
Cloning of E6F47R into the pFP recombination plasmid 
The pCR-BluntII-TOPO/E6F47R plasmid was cut with HindIII (Fermentas), and after 
separation on 0.8% agarose gel, the E6F47R gene (477 bp) was ligated with the pFP 
plasmid vector, previously linearized with the same restriction enzyme. The linearized pFP 
vector was dephosphorylated by using 1 μg of DNA/1 U of alkaline phosphatase (CIP, 
Boehringer Mannheim) at 37 °C for 30 min, to avoid self-ligation events. After inactivation 
of the enzyme at 65 °C for 15 min, the vector was resuspended in bidistilled water. 
The insertion of E6F47R gene in the pFP plasmid was performed by using 100 ng of insert 
and an insert:vector molar ratio of 3:1, and 1 U of T4 DNA ligase (USB, Cleveland, OH) in 
a final volume of 10 μL. The ligation reaction was performed at 16 °C o/n, and the ligation 
product was used to transform DH5α competent bacteria by heat shock, as already 
described. Aliquots of bacteria were seeded in Petri dishes containing agarized LB and 
ampicillin (100 μg/mL), and incubated at 37 °C o/n. Some bacterial clones were 
transferred in liquid growing media and incubated at 37 °C for 1 h, and the presence of the 
insert was evaluated by PCR using the forward V62 (5’ ggt tct tga ggg ttg tgt 3’) and the 
reverse V104 (5’ gga gat gcg atg ata aga gga 3’) primers, which are complementary to the 
pFP plasmid sequences. The amplification was performed by denaturation at 94 °C for 4 
min, followed by 30 cycles at 94 °C for 30 sec, 52 °C for 30 sec and 72 °C for 1 min, and 
one final cycle at 72 °C for 7 min. A few positive clones were added of 1 mL of LB with 
ampicillin and grown at 37 °C o/n. The plasmid DNA was extracted from the clones by 
minilysates and analyzed by evaluating the fragments pattern obtained after enzymatic 
digestion. The presence and orientation of the gene was confirmed by digestion with 
HindIII and SalI (Fermentas), and separation of the fragments in 0.8% agarose gel. The 
plasmid DNA of one positive clone was sequenced to exclude the presence of mutations, 
and the obtained recombination plasmid was called pFPE6F47R. 
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pFPE7GGG  
 
The pFPE7GGG recombination plasmid (Fig. 13) was generated by insertion of the E7GGG 
gene down-stream of the VVH6 promoter. PE7GGG, kindly provided by Dr. A. Venuti 
(Istituto Nazionale Tumori Regina Elena, IFO, Roma, Italy), was obtained by substituting 
the DLYCYE motif (amino acids 21-26) that is located in the CR2 homology domain by the 
GLYGYG sequence. This mutation prevents pRb binding and oncogenicity of the E7 
protein. 
 
 
 
 
 
 
 
 
 
Fig. 13.  Map of the pFPE7GGG recombination plasmid  
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pFPE7GGG construction 
 
Amplification of the E7GGG insert 
The E7GGG gene was prepared by PCR using the expression plasmid pcDNA3.1-E7GGG as 
a template. The amplification was performed using the forward V302 (5’ gcc gcg ccc ggg 
aag ctt atg cat gga gat aca cct aca tt 3’) and the reverse V303 (5’ gcc gcg gtc gac aag ctt 
tta tgg ttt ctg aga aca gat gg 3’) primers, which were designed to be complementary with 
the terminal regions of the E7GGG gene and to contain at the ends two enzymatic restriction 
sites and allow the subsequent insertion in the pFP vector. The PCR reaction was 
conducted at the final condition of 1 mM MgCl2, 200 μM dNTPs, 1 μM primers and 0.025 
U/μL Pwo polymerase in buffer containing MgSO4, using the PTC-200 Thermo Cycler. The 
amplification was performed by denaturation at 94 °C for 1 min, followed by 24 cycles at 
94 °C for 30 sec, 58 °C for 30 sec, 72 °C for 30 sec, and one final cycle at 72 °C for 7 min. 
 
Cloning of E7GGG into the pFP recombination plasmid 
The amplified E7GGG gene as well as the pFP plasmid vector were cut with HindIII 
(Fermentas) and incubated at 37 °C for 1 h. After buffer removal and resuspension in 
bidistilled water, the pFP vector was dephosphorylated, as already described, to avoid the 
occurrence of self-ligation events. The insertion of the E7GGG gene into pFP was 
performed by ligating 100 ng of E7GGG and an insert:vector molar ratio of 3:1 in the 
presence of 1 U of T4 DNA ligase (USB) in a final volume of 10 μL. The reaction was 
conducted o/n at 16 °C and the ligation product was used to transform DH5α competent 
bacteria, as already described. The seeding of bacteria, clones growth and isolation, and 
the subsequent plasmid DNA extraction was performed as already described. The 
presence and orientation of the insert was verified by PCR amplification using the forward 
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primer V62, which recognizes the promoter sequence, and the reverse V101 primer (5’ 
cga agc ttt tat ggt ttc tga gaa cag 3’), which is complementary to a gene fragment. One 
positive clone was chosen sequenced to verify the absence of mutations and called 
pFPE7GGG. 
  
Plasmid DNA amplification and purification 
The production of a high amount of plasmid DNA and its purification was performed by 
alkaline lysis followed by ultracentrifugation on a CsCl gradient. Briefly, bacterial clones 
containing the right plasmid, were grown at 37 °C o/n in 750 mL of LB medium in the 
presence of ampicillin (100 μg/mL), and centrifuged at 6,000 x g at 4 °C for 10 min. The 
pellet was resuspended in 18 mL of cold STE buffer (50 mM glucose, 25 mM Tris HCl pH 
8  10 mM EDTA), added of 42 mL of lysis buffer (100 mM NaOH and 10% SDS), and 
incubated at room temperature for 5 min, and then, at 4 °C for 5 min. The mix was added 
of 21 mL of cold 3 M CH3COOK, pH 4.8, incubated at 4 °C for 10 min, and bacteria debris 
were sedimented by centrifugation at 7,000 x g at 4 °C for 10 min. The supernatant, 
filtered on gauzes, was added of 0.6 volumes of isopropanol to precipitate the DNA, and 
then centrifuged at 7,000 x g at 4 °C for 15 min. To obtain a purified plasmid DNA, the 
pellet was resuspended in 3.8 mL of TE buffer (10 mM Tris HCl and 1 mM EDTA, pH 8), 
added of 1 g/mL of CsCl and 2.5 mg/mL of EtBr, and then ultracentrifuged on NVT-90 
vertical rotor (Beckman Coulter, Milan, Italy) at 60,000 rpm at 24 °C o/n. The plasmid DNA 
band, detectable using an UV lamp was extracted and washed three times using a volume 
of isopropanol. The aqueous phase, containing the DNA, was added of 2 volumes of TE 
buffer and 1.5 volumes of 100% EtOH, to allow the plasmid DNA precipitation, and then 
centrifuged at 10,000 x g at 4 °C for 30 min. Finally, the pellet was washed with 70% 
EtOH, drayed and resuspended in bidistilled water. 
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pcDNA3E6F47R and pcDNA3.1E7GGG 
 
The pcDNA3E6F47R and pcDNA3.1E7GGG expression plasmids, containing the same 
mutated E6F47R or E7GGG sequences of pFPE6F47R or pFPE7GGG recombination plasmids, 
were used for the mice immunizations. These plasmids were generated from pcDNA3 or 
pcDNA3.1 (Life Technologies Corp., Carlsbad, CA, USA), by insertion of the E6F47R or 
E7GGG genes. They were propagated in E. coli and extracted by alkaline lysis, followed by 
purification and endotoxin removal (Qiagen, EndoFree Plasmid Giga Kit).  
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Virus 
 
Construction of the FPE6F47R and FPE7GGG recombinants 
 
The viral recombinants were generated by homologous site-specific recombination, which 
occurred between the FPwt and the pFPE6F47R or pFPE7GGG recombination plasmids. 
During this event, the DH gene is inactivated by the insertion of the heterologous gene 
downstream of the VVH6 promoter. 
 
Site-specific homologous In Vitro Recombination (IVR) 
The recombination events occur between the FPwt DNA genome and the DNA 
recombination plasmid in the cytoplasm of CEFs, after viral infection and plasmid 
transfection by the CaPO4 method (Fig. 14). 
To this aim, CEFs grown to sub-confluency were washed once with PBS-, infected with the 
FPwt virus (5 pfu/cell) in a final volume of 200 μL of Earle’s Balanced Salt Solution (Earle’s 
BSS) and incubated at 37 °C for 1 h. After the incubation, cells were added of growing 
medium supplemented with 2.5% CS and 2.5% TPB, and incubated for 3 h.  
The transfection was performed after preparing 62.5 μg plasmid, and 125 mM CaCl2 in 
HEBS pH 7 (20 mM Hepes, 150 mM NaCl, 0.7 mM Na2HPO4, 5 mM KCl and 6 mM 
dextrose) in a final volume of 500 μL, which was maintained at room temperature for 30 
min. After incubation, the transfection solution was distributed onto the infected CEFs, and 
left at 37 °C for 3 h. Cells were then washed once with PBS-, and DMEM supplemented 
with 2% FCS was added. Cells were maintained in incubator for 48 h, and then lysed by 
freeze/thawing three times. Cell debris were removed by centrifugation at 2,000 x g at 4 °C 
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for 15 min, and the supernatant, diluted from 1:1,000 to 1:3,000 with growing medium, was 
used to infect confluent CEFs for 1 h at 37 °C. After infection, each Petri dish was added of 
5 mL of DMEM supplemented with 2.5% CS, 2.5% TPB and 0.7% LE agarose (SeaKem, 
FMC BioProducts, Rockland, ME). At the third day post infection (p.i.), each Petri dish was  
added of additional 5 mL of agar medium supplemented with 1.5% Neutral Red (RN, 
Gibco), for a better visual detection of the viral plaques of lysis.  
 
 
 
 
Fig. 14.  In-Vitro Recombination (IVR)  
Schematic representation of the events occurring during the IVR. Briefly, the presence of the 
recombination plasmid and the genome of the wild-type virus inside the same cell leads to 
the site-specific transfer of the heterologous gene into the genome of the wild-type virus and 
allows the formation of a new recombination virus. 
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Purification of FP recombinants  
To the aim of obtaining 100% pure clones of the viral recombinants, several rounds of 
plaque-purification were performed by the following passages:  
 
- Replica plating 
The agarized medium was removed from the Petri dishes, and a nitrocellulose 
membrane (Protran BA 85 0,45 μm, Schleicher & Schuell, Whatman, NJ) was laid down 
on the cell layer. A 3MM paper filter (Whatman), pre-soaked of transfer buffer (50 mM 
Tris HCl, pH 7.5 and 150 mM NaCl), was gently positioned over the membrane to allow 
the transfer of the virus onto the nitrocellulose membrane. Filter and membrane were 
removed from the dish and a second nitrocellulose membrane, defined “replica 
membrane”, was laid down on the first membrane, defined “original membrane”. The 
original membrane was used to detect the recombinant viral plaques by hybridization 
with a 32P-labelled probe, whereas the replica membrane was stored at -20 °C and used 
to isolate the positive plaques, which were detected as a spot onto a radiography film. 
 
- Membrane denaturation 
The original membranes were denatured with 0.5 M NaOH, neutralized twice with Tris 
HCl 1 M pH 7.6, and twice with a solution of 100 mM Tris HCl, pH 7.6, and 150 mM 
NaCl. Each treatment was performed for 5 min, allowing the membranes to air-dry 
between a step and the other. 
 
- Preparation and 32P probe labeling  
The probes were obtained by PCR amplification of a gene fragment. In particular, for 
the E6F47R gene the forward primer V348 (5’ ctg caa tgt ttc agg acc 3’) and the reverse 
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primer V350 (5’ ata cat cga ccg gtc cac 3’) were used, whereas for E7GGG the forward 
primer V302 and the reverse primer V303 were utilized. The probes’ labeling was 
performed using the Multiprime labelling system (Amersham International, 
Buckinghamshire, UK), following the manufacturer’s instructions, and the 32P-dCTP as a 
labelled nucleotide (Perkin Elmer, Norwalk, CT). 
 
- Hybridization and autoradiography  
The denatured original membranes were incubated at 60 °C for 1 h in hybridization 
buffer (4X SSC, 0.1% SDS, 0.1% NaPP, 100 μg/mL salmon sperm DNA and 5X 
Denhardt solution), then added of the radiolabelled probe, and incubated o/n at the 
same temperature. The exceeding probe was removed by washing at 60 °C for 2 h 
using a washing buffer (0.2X SSC, 0.2% SDS, and 0.2% NaPP). Membranes were left 
on 3MM paper to air-dry and overlaid with a photographic film (Biomax MS, Amersham 
International) o/n at -80 °C before film development.  
 
- Isolation of the recombinant clones  
The autoradiography-positive plaques were localized on the original membranes, 
detected on the corresponding replica membranes and excised using a cutter. Each 
plaque was transferred in 1 mL of Earle’s BSS containing 0.06% trypsin, incubated at 
37 °C for 5 min and sonicated for 1 min using a Sonicator W-385 (Heat Systems-
Ultrasonic, Inc, Farmingdale, NY) to allow the rescue of the recombinant clone. The viral 
suspension was then serially diluted 1:10 to infect confluent CEFs. 
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Amplification of recombinant clones  
Some clones of FP recombinants, obtained by plaque purification, were amplified to the 
aim at verifying their ability to express the heterologous gene. CEFs were infected with 
200 μL of virus suspension and after 4 days, cells were lysed by freeze/thawing three 
times, to allow the virus release. Cell debris were removed by centrifugation at 2,000 x g at 
4 °C for 15 min and the virus supernatant was used to analyze the protein expression of 
the foreign gene before proceeding to the production of a high amount of the chosen viral 
clone. 
 
Large-scale amplification of viral clones 
 
The large-scale production was performed on confluent primary CEFs (1.4 x 107 cell/Petri 
dish). The cells were infected by using each viral clone (0.2 PFU/cell) diluted in a final 
volume of 500 μL Earle’s BSS/Petri dish, and incubating at 37 °C for 1 h. At the end of the 
incubation, each Petri dish was added of 5 mL of DMEM supplemented with 2.5% CS and 
2.5% TPB. When the cytopathic effect was detectable (5 days p.i.), cells were harvested 
using a rubber cell harvester, centrifuged at 30,000 x g at 4 °C for 1 h, and pellets were 
frozen at -80 °C. After thawing, pellets were treated with 0.06% trypsin in TNE (0.001 M 
Tris, 0.15 M NaCl, 0.001 M EDTA, pH 7.4) at 37 °C for 5 min. To allow the viral release 
from the pellet, cells were sonicated several times (20 sec for 3-5 times). For purification, 
the viral suspension was layered onto a discontinuous sucrose gradient (30-45% w/w) and 
ultracentrifuged at 38,000 x g at 4 °C for 1 h. The viral band at the interface was 
harvested, washed with 0.001 M Tris HCl pH 9, and sedimented at 67,000 x g at 4 °C for 1 
h to remove the residual sucrose,. The viruses were resuspended in PBS-, sonicated, 
aliquoted, stored at -80 °C, and titred. 
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Virus titration  
 
The evaluation of the recombinant concentration was performed by viral titration, in 
duplicate on confluent CEFs grown into 5-cm-diameter Petri dishes. Cells were infected 
with serial dilutions of the virus, from 10-3 to 10-8, in 200 µL of Earle’s BSS, incubated at 37 
°C for 1 h, and then, added of agar medium (5 mL/Petri). After 3 days, a new layer of agar 
medium was added (5 mL/Petri), supplemented with NR. After 24 h, the plaques were 
counted where the virus dilution allowed the optimal plaque separation. The viral 
concentration was expressed as PFU/mL and worked out by the formula: mean of the 
plaque numbers x dilution factor x volume conversion factor.  
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Assays 
 
mRNA isolation 
 
The mRNA was extracted from infected-cells (CEF, Vero and MRC-5) by Trizol LS 
(Gibco). Cells were infected (1 PFU/cell) with the different viral recombinants and, after a 
24-h incubation, the mRNA extraction was performed following the manufacturer’s 
instructions. Briefly, cell samples, stored at -80 °C, were thawed and added of 80 µL of 
chloroform. After incubation at 4 °C for 5 min and centrifugation at 12,000 x g at 4 °C for 
15 min, the aqueous phase, containing the RNA, was transferred in new RNase-free 
tubes. The RNA was precipitated by adding 2 volumes of isopropanol, incubated at 4 °C 
for 15 min, and then centrifuged at 12,000 x g at 4 °C for 15 min. The RNA pellet was 
washed with 70% EtOH, centrifuged at 7,500 x g at 4 °C for 5 min, drayed and 
resuspended in water treated with dietilpirocarbonate (DEPC). Samples were stored at -20 
°C o/n, and then analyzed by electrophoresis separation in 1% agarose gel to evaluate the 
integrity of the bands, and by spectrophotometer to assess the RNA concentration. 
 
RT-PCR 
 
The E6F47R and E7GGG gene expression was evaluated by RT-PCR of RNA samples 
extracted from infected cell lines. The amplification was performed by the Access RT-PCR 
System (Promega, Madison, WI) using 50 ng of RNA in a final volume of 10 μL. The 
amplification of the E6F47R transcript was performed by using the forward primer V348 (5' 
ctg caa tgt ttc agg acc3’) and the reverse primer V99 (5’ cga agc ttt tac agc tgg gtt tct cta 
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cg 3’). For the E7GGG transcript, the forward V302 and the reverse V303 primers were 
used. The RT-PCR reaction was performed at the final condition of 200 μM dNTPs, 1 μM 
primers, 0.1 U/μL AMV reverse-transcriptase, 0.1 U/μL TLF DNA polymerase. MgSO4 was 
used at 2.5 mM for E6F47R, and at 2 mM for E7GGG. The reverse-transcription step was 
conducted at 48 °C for 45 min, followed by a step at 94 °C for 2 min to inactivate the 
enzyme. The E6F47R amplification was performed by 40 cycles at 94 °C for 30 sec, 55 °C 
for 30 sec and 68 °C for 30 sec, whereas for E7GGG the annealing and the extension were 
performed at 58 °C for 30 sec and 68 °C for 30 sec, respectively. The final cycle was 
performed at 68 °C for 7 min. 
RNAs extracted from mock- or FPwt-infected cells were used as negative controls, 
whereas RNAs extracted from pSG5-E6F47R or pcDNA3.1-E7GGG plasmid-transfected cells 
were used as positive controls. 
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SDS-PAGE and Western blotting 
 
CEF, Vero and MRC-5 confluent cells were infected with the different viral recombinants or 
with FPwt (10 PFU/cell) and incubated at 37 °C for 1 h. After infection, 5 mL/Petri dish of 
DMEM supplemented with 2.5% CS were added to each dish and cells were incubated at 
37 °C o/n. Cells were washed once with PBS-, lysed with 300 μL/Petri of 2X lysis buffer 
(0.05 M Tris HCl, 2% SDS, 10% glycerol, 1.5% DTT, 0.05% bromophenol blue) and 
harvested. After an incubation at 100 °C for 5 min, cells were cooled at 4 °C to complete 
the lysis. Samples were loaded in a 15% acril/bisacrilamide gel and run at 40 mA for 3 h in 
cold buffer (0.025 M Tris HCl, 0.192 M glycine, 0.1% SDS). The separated proteins were 
transferred on a 0.2 μm nitrocellulose membrane (NC, Trans-Blot Transfer Medium, Bio-
Rad Laboratories, Hercules, CA) for 1 h at 100 V in cold buffer and by using a transfer 
device (Trans-Blot Electrophoretic Transfer Mini Cell, Bio-Rad). The NC was then 
processed by treating with 0.5% glutaraldehyde (Polysciences, Warrington, PA) for 30 min 
with gentle stirring, followed by washing with distilled water and saturation for 1 h with a 
buffer containing 5% skimmed milk in PBS- 1X. The NC was then washed shortly with 
wash buffer (0.1% Tween-20 in PBS- 1X) and incubated at 4 °C o/n with the primary 
antibody diluted in 1% milk plus 0.1% Tween-20 in PBS- 1X. The identification of E6F47R 
was performed using a 1:100-dilution of the mouse polyclonal AbE6/Gi primary antibody 
(C. Giorgi, Istituto Superiore di Sanità, Rome, Italy). For E7GGG, a 1:100-dilutions of the 
ED17 (AbE7/SC, Santa Cruz Biotechnology, CA, USA) or the 8C9 (Zymed Lab., 
Invitrogen) monoclonal antibodies were used. After 30 min washing, the NC membranes 
were incubated at room temperature for 1 h with a 1:2,000-dilution of the goat anti-mouse 
horseradish peroxidase (HRP) conjugated secondary antibody (Dako Cytomation, 
Carpinteria, CA, USA) and washed for 2 h, before the proteins were revealed by the ECL 
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system (GE Healthcare, Buckinghamshire, UK). Cells infected with FPwt were used as a 
negative control, whereas the E6/E7 proteins, CaSki cell lysates or FPE7-infected cell 
lysates [119] were used as positive controls. 
 
Immunofluorescence 
 
CEF, Vero and MRC-5 cells were seeded in 6-well plates on cover glasses, previously 
dipped in 100% EtOH and flame-sterilized. After 16/18-h incubation, cells were infected (5 
PFU/cell) with the different recombinants. FPwt-infected cells were used as a negative 
control, and, to detect the E7GGG expression, FPE7-infected Vero cells [85] were used as a 
positive control. After infection, cells were added of DMEM supplemented with 2% FCS 
and incubated o/n. After washing twice with PBS-, cells were fixed with 2% formaldehyde 
(methanol-free ultrapure Formaldehyde, Polysciences) in PBS-, incubated at room 
temperature for 10 min, at 4 °C for 5 min in wash buffer (0.2% BSA plus 0.1% NaN3 in 
PBS+ 1X), and then fixed again in cold acetone at 4 °C for 5 min. After 3 washing steps, 
fixed cells were incubated with the primary antibodies for 1 h in a humidified room. The 
detection of E6F47R was performed using a 1:100-dilution of AbE6P/Gi, whereas for E7GGG, 
a 1:100-dilution of a mixture of ED17/8C9 monoclonal antibodies was used or, 
alternatively, the FPwt-immunoadsorbed rabbit anti-E7 specific polyclonal antibody, 
produced in our laboratory. The exceeding antibodies were removed by 3 washing steps, 
and a 1:100-dilution of the Fluorescein IsoThioCyanate (FITC)-goat anti-mouse or anti-
rabbit antibodies (Dako Cytomation). After incubation and 3 washing steps, and a final-one 
in distilled water, the cover glasses were laid on a drop of a maintaining solution (80% 
glycerol, 3% N-propyl-gallate in 20% PBS+, pH 7.4). FPwt-infected cells were used as a 
negative control, whereas FPE7-infected Vero cells were used as a positive control to 
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detect the E7GGG protein. The samples were viewed under a Zeiss Axioskop fluorescence 
microscope. 
 
Production of E6 and E7 proteins  
  
The E6 and E7 recombinant proteins, bound to an Histidine tag were produced using E. 
Coli JM109 bacteria, containing the pQE30-E6-His or pQE30-E7-His plasmid, following the 
manufacturer’s specifications (Qiagen), with minor modifications. Briefly, bacteria were 
grown in 50 mL of LB supplemented with 100 μg/mL ampicillin at 37 °C o/n. The culture 
was then added of 450 mL of fresh medium at 37 °C for 1 h until the optical density of 0.6-
0.7 was reached, as measured by a spectrophotometer at 600 nm. The protein production 
was induced by 2 mM IPTG at 37 °C for 3 h, and, after centrifugation at 4,000 x g at 4 °C 
for 30 min, the bacterial pellet for the E6 protein was resuspended in buffer A (HCl 6 M 
Guanidine, 0.1 M NaH2PO4 x H2O, 10 mM Tris HCl, pH 8), and the pellet for the E7 protein 
in buffer B (100 mM NaH2PO4 x H2O, 10 mM Tris HCl, 8 M Urea, pH 8) before freezing at -
80 °C o/n. The pellet was then 1:2-diluted with a lysis solution (0.3 M NaCl, 1% Triton-X-
100 in buffer A or B), and incubated at room temperature for 30 min on an orbital shaker. 
The solution was then sonicated for 1 h, and the lysate was centrifuged at 14,000 x g at 4 
°C for 30 min. The supernatant was added of 1% Triton-X-100 and imidazole 20 mM pH 8, 
and incubated at room temperature for 30 min with a Ni-NTA Agarose resin (Qiagen), 
previously resuspended in buffer A or B. The resin, bound to the protein, was centrifuged 
at 800 x g at 4 °C for 5 min, washed once with 1% Triton-X-100, diluted in buffer A or B, 
and twice with buffer C (100 mM NaH2PO4 x H2O, 10 mM Tris HCl, 8 M Urea, pH 6.3), and 
then loaded on a column. The protein was eluted from the resin with different fractions of 1 
M imidazole, pH 8, and subsequently analyzed by SDS-PAGE to detect which ones 
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contained the protein of interest. The positive fractions were mixed together and dialyzed 
against PBS- to remove the imidazole. 
The protein quantification was performed in 96-well plates after preparing standard 
samples with a known concentration of Bovine Serum Albumin (BSA) to the aim at 
generating a calibration standard curve from 0.2 to 20 mg/mL. Four wells were loaded with 
2 μL/each of protein solution in 20 μL water. After adding 200 μL/well of reaction mixture 
(Pierce, Rockford, IL, USA), and incubating at 37 °C for 30 min, measurements at 570 nm 
were performed using a spectrophotometer.    
 
 
Immunization protocol and challenge with TC-1* tumor cells 
 
Two protocols were followed for each mutated protein using six-week-old C57Bl/6 female 
mice (Charles River Laboratories, Como, Italy). First is referred to as the immune 
response protocol, in which the mice were bled before each immunization to evaluate the 
induced humoral response by ELISA. These mice were finally sacrificed to obtain 
splenocytes for the enzyme-linked immunospot (ELISPOT) and determine the cellular 
response. The second regimen is referred to as the therapeutic immunization protocol, in 
which the mice were inoculated with E6/E7-expressing TC-1* tumor cells before 
administration of the immunogens. The tumor volume and growth was monitored during 
the whole experiment.  
 
Immune response protocols  
In the immune response protocol, the immunizations were performed to evaluate the 
response induced by E6F47R-based immunogens (Fig. 15 A). Mice were divided in three 
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groups of six animals each, and they were primed with the recombinant pDNAE6F47R 
plasmid once (protocol GA.1; 100 µg/mouse, intramuscular, i.m.) or twice (protocol GA.2; 
100 µg/mouse, i.m.). Two weeks after the DNA inoculation, the animals were boosted 
twice (protocol GA.1) or once (protocol GA.2) with FPE6F47R (107 PFU/mouse, 
subcutaneous, s.c.). All of the mice remained in good health, and, after the last 
immunization, the mice of each group were sacrificed to obtain splenocytes. The control 
mice (protocol GA.3) were repeatedly mock-infected.  
In the E7GGG immune response protocol (Fig. 15 B), mice were divided into three groups of 
eight animals each. The mice were primed with the recombinant DNAE7GGG plasmid 
(protocol GB.2; 100 µg/mouse, i.m.) or with the recombinant FPE7GGG virus (protocol 
GB.3; 107 PFU/mouse, s.c.), and boosted three times at 2-week intervals with FPE7GGG 
virus (protocol GB.2 and GB.3; 107 PFU/mouse, s.c.) one week after the first inoculation. 
The mice for protocol GB.1 were mock-vaccinated and used as controls. After the last 
immunization, the mice were still in good health, and they were sacrificed to perform the 
ELISPOT assays. 
 
Therapeutic immunization protocols  
In the therapeutic protocol, the immunizations were performed to evaluate the therapeutic 
efficacy of E6F47R-based immunogens (Fig. 15 C), and four groups of five mice were 
inoculated by s.c. injection of 5×103 TC-1* cells in a final volume of 200 µL saline solution. 
TC-1* were previously found to induce tumors in 100% of the mice [60]. After three and ten 
days, mice were immunized twice with DNAE6F47R (protocol GC.1; 100 µg/mouse, i.m.) or 
with DNAE6F47R followed by FPE6F47R (protocol GC.2; 107 PFU/mouse, s.c.) or twice with 
FPE6F47R (protocol GC.3; 107 PFU/mouse, s.c.). The mice for protocol GC.4 were mock 
vaccinated and used as controls.  
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In the therapeutic protocol for E7GGG (Fig. 15 D), three groups of five or six mice were 
inoculated by s.c. injection of 5×103 TC-1* cells in a final volume of 200 µL saline solution. 
After three days, the mice were primed once with either DNAE7GGG (protocol GD.2; 100 
µg/mouse, i.m.) or with FPE7GGG (protocol GD.3; 107 PFU/mouse, s.c.). Boosting was 
performed one week after the priming, using FPE7GGG (protocol GD.2 and GD.3; 107 
PFU/mouse, s.c.). The mice for protocol GD.1 were mock vaccinated and used as 
controls.  
In both the therapeutic protocols, tumor growth was monitored after immunization by visual 
inspection and palpation twice a week. Tumor size was measured with calipers starting 
from 3 to 4 weeks post challenge (p.c.), and the volume estimated by the formula (width × 
length × (width + length)/2). Animals were scored as tumor-bearing when tumors reached 
a size of approximately 1 to 2 mm in diameter and were euthanized for ethical reasons 
when tumors reached a 2-cm3 volume. All of the mice were housed and handled under 
specific pathogen-free conditions, in accordance with the European guidelines for the 
protection of laboratory experimental animals and laboratory animal care. 
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Fig. 15.  Immunization protocols 
 
In the immune response protocols, mice were first primed and boosted at one- or two-week 
intervals, with plasmid or viral recombinants expressing the E6F47R (A) or E7GGG (B) gene. 
 
In the therapeutic protocols, mice were challenged with TC-1* cells, primed once three days 
after challenge, and boosted one week after the priming, using plasmid or viral recombinants 
expressing the E6F47R (C) or E7GGG (D) gene.  
Bleedings are indicated as black triangles, whereas spleen removal for ELISPOT assays as 
empty triangles. 
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ELISA 
 
The mice sera were tested for the presence of antibodies against the E6 and E7 proteins 
before the first and after each immunization. The purified native pE6 or pE7 proteins (300 
ng/well), or the CaSki cells lysates (105 cells/well), were adsorbed onto 96-well MaxiSorp 
microtitre plates (Nunc, Naperville, IL, USA) incubated at 4 °C o/n in a 100-µL Coating 
Buffer (CB, 15 nM Na2CO3, 35 nM NaHCO3, 0.2% NaN3, pH 9.6) or PBS-. After the 
incubation, wells were washed six times with Wash Buffer (WB, 0.8% NaCl, 1.5 nM 
KH2PO4, 2.7 nM KCl, 8.0 nM Na2HPO4 (xH2O), 0.05% Tween-20) saturated with 3% 
skimmed milk in PBS-, incubated at 37 °C for 1 h and washed again. Each well was added 
of 100 µL of sera, 1:50- or 1:100-diluted in WB containing 0.3% skimmed milk, and 
samples were incubated at 37 °C for 1 h. The plates were then washed 6 times, added of 
100 µL of 1:2,000-diluted goat anti-mouse HRP-conjugated antibodies (Dako), and left at 
37 °C for 1.5 h before washing again as before. 100 µL of tetra-methyl-benzidine (TMB) 
substrate (Sigma) were then added and the plate was incubated at room temperature for 
30 min in a dark room. The reaction was blocked with 25 µL/well of 2 M H2SO4, and the 
absorbance was measured at 450 nm using a 550 microplate reader (Bio-Rad 
Laboratories). 
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ELISPOT assay for IFN-γ-secreting cells 
 
HPV16 E6- and E7-specific T-cell precursors were detected by the ELISPOT assays for 
IFN-γ-secreting cells (BDTM ELISPOT, BD Biosciences Pharmingen) [120]. Mice were 
euthanized by cervical dislocation one week after the last immunization and splenocytes 
were harvested. Briefly, after removal of the exceeding adipose tissue, spleens were 
mashed, passed through a 100-µm cell strainer, and splenocytes harvested in PBS- before 
centrifuging at 300 x g at 4 °C for 5 min. Cell pellet was resuspended in RPMI medium 
(Gibco) supplemented of 10% FCS and P/S (R10) and a single-cell suspension of 
splenocytes from each group was added to microtiter wells (106 cells/well in 100 µL of 
R10) that had been pre-coated with an anti-mouse-IFN-γ antibody (5 µg/mL; BD 
Biosciences Pharmingen) along with IL-2 (50 units/mL; Sigma) at 4 °C o/n. The pre-
coating was performed by diluting capture antibodies and IL-2 in a final volume of 100 
µL/well of Coating Buffer (PBS-) and the plate incubated at 4 °C o/n. The plates were then 
washed with R10 and incubated at room temperature for 2 h with 100 µL/well of R10. After 
discarding R10, each well was added a stimulation antigen in a final volume of 100 µL/well 
of R10, and the splenocytes. The stimulation to detect the T-cell precursor induced by 
E6F47R immunization was performed using either pE6 in three different concentrations (0.1, 
1.0, 10 µg/mL) or two E6-specific epitopes (aa 50-57, aa 18-26) [121,122]. Stimulation to 
detect T-cell precursors induced by the E7GGG immunization was performed using two 
different concentrations (1 µg/mL and 10 µg/mL) of either the E7-specific H2Db CTL MHC 
class I epitope (RAHYNIVTF, aa 49-57) [123] to detect CD8+ T-cell precursors, or the 
MHC class II peptide (aa 30–67) to detect CD4+ T-cell precursors [124,61]. Stimulations 
were performed in triplicates at 37 °C for 24-72 h. An unrelated protein (scFv) was used as 
a negative control. After incubation, cell suspensions were removed, and each well was 
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washed twice with deionized water and three times with Wash Buffer (0.05% Tween-20 in 
PBS-). The plates were incubated with a biotinylated anti-mouse IFN-γ antibody in a final 
volume of 100 µL/well (2 µg/mL; BD Biosciences Pharmingen) at room temperature for 4 
h. After removal of detection antibodies, wells were washed three times with PBS-, added 
of 100 µL/well of Streptavidin-HRP and incubated at room temperature for 1 h. 
Streptavidin-HRP solution was discarded and wells were washed as previously described, 
before adding 100 µL/well of the 3-amino-9-ethylcarbazole (AEC) substrate and monitoring 
the spot development in the next 1 to 5 min. The reaction was stopped by washing with 
deionized water, and, after air-drying in the dark, the spots were counted under a 
dissecting microscope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
RESULTS 
 
Cloning of the E6F47R sequence into the recombination pFP vector 
 
To the aim at cloning the E6F47R gene into the pFP recombination plasmid, three different 
strategies were followed.  
The E6F47R was first amplified by PCR from the pSG5-E6F47R plasmid, using primers which 
allowed the generation, at the ends of the gene, of two restriction sequences compatible 
with the ones contained into the multicloning site of the pcDNA3 intermediate and the final 
pFP recombination vector. During these steps, both the sub-cloning of the exogenous 
gene into the intermediate vector and the direct cloning into pFP failed in that all of the 
obtained clones did not contain the correct plasmid and two alternative strategies were 
pursued. 
First, the E6F47R gene was excised from the starting plasmid pSG5-E6F47R, ligated to an 
intermediate vector, and excised again, to be inserted into the pFP recombination vector. 
By this strategy, some clones were isolated that contained the insert in the correct 
orientation. The electrophoretic separation, performed after enzymatic digestion of the 
intermediate sub-cloning vector, showed the presence of a 751-bp specific band in 13 
clones out of the 16 examined (Fig 16, Panel A, lanes 1-4, 6-12, 14-15), whereas when 
performed on the final pFP vector, 9 out of 14 colonies showed the presence of a 956-bp 
specific band (Fig 16, Panel B, lanes 1, 3-7, 10, 12-13). 
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Fig. 16.  Analysis of the presence of the E6F47R insert by gel electrophoresis 
(second strategy) 
 
A. PCR analysis of E6F47R clones in the intermediate pcDNA3 vector: 13 positive clones were 
positive out of 16. 
B) PCR analysis of E6F47R clones in the recombination pFP vector: 9 positive clones were 
positive out of 14 
 
M, molecular weight marker, 100 bp 
C+, positive control (pcDNA3 containing an exogenous gene (A) and pFPE6 (B) 
C-, negative control (empty pFP) 
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Following an alternative cloning strategy, the E6F47R gene was amplified by PCR and 
directly used, without purification, to ligate the blunt ends to the intermediate pCR-BluntII-
TOPO vector. The correct 720 bp- band was identified in 29 clones out of 30 (Fig. 17, 
Panel A lanes 1-8 e 10-30).  
Six clones were chosen and further analyzed by two different enzymatic digestions. The 
first, using EcoRI, showed two bands of 501 and 3,932 bp, confirmed the presence of the 
insert (Fig. 17, Panel B, lanes 1-6 EcoRI), whereas the second, performed with HindIII, 
showed two bands of 477 and 3,956 bp, respectively, demonstrated not only the presence 
of the insert, but also the maintenance of the restriction sequences flanking the E6F47R 
gene, and necessary for the subsequent cloning steps (Fig. 17, Panel B, lanes 1-6 HindIII). 
The E6F47R gene was then excised from one of the selected clones by cutting with the 
HindIII, and inserted into pFP, which was previously cut with the same enzyme. The 
presence of the recombinant gene, verified by PCR, highlighted a 956-bp band in 7 clones 
out of 19 (Fig. 17, Panel C, lanes 1-3, 7-9, 11-13, 15-18). Two different enzymatic 
digestions confirmed the presence of the exogenous gene in all of these clones. In 
particular, HindIII digestion showed in each selected clone, a band of 8,209 bp 
corresponding to the vector, and the specific 477-bp band of the insert (Fig. 17, Panel D, 
lanes 1-7 HindIII). Conversely, the SalI digestion, showed the presence of the E6F47R gene 
in the right orientation only in 2 clones (Fig. 17, Panel D, lanes 4-5 SalI) by the presence of 
a 417-bp and a 8,269-bp bands. Both the positive clones were sequenced and no 
mutations in were evidenced.  
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 Fig. 17.  Analysis of the presence of E6F47R transgene by gel electrophoresis  
 (third strategy) 
 
PCR analysis of E6F47R clones in the intermediate pCR-BluntII-TOPO vector. (A) 29 positive 
clones were positive out of 30. (B) The presence of the transgene was confirmed by 
enzymatic digestion with EcoRI and HindIII. 
 
PCR analysis of E6F47R clones in the recombination pFP vector. (C) 7 positive clones were 
positive out of 19 clones. (D) The presence of the transgene and its correct orientation was 
confirmed by enzymatic digestion with HindIII and SalI.  
 
M o M1, molecular weight marker, 100 bp 
M2, molecular weight marker, 1 kb 
C+, positive control (pFPE6) 
U, uncut plasmid 
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Cloning of the E7GGG sequence into the recombination pFP vector 
 
The cloning of E7GGG gene into the pFP recombination vector was performed after PCR 
amplification of the transgene, cut by restriction enzymes and its direct insertion into the 
vector. To the aim at evaluating the correct cloning of the insert, a screening was 
performed by PCR using a primer complementary to the VVH6 promoter sequence, 
present on the vector, and a primer complementary to the transgene. This allowed the 
visualization of positive clones and of the correct orientation of them. After running in 
agarose gel, the expected 400-bp sequence was shown in 8 out of 44 clones (Fig. 18, 
lanes 3, 12, 25-27, 38, 43-44). Sequencing was also performed, which confirmed the 
absence of mutations into the whole sequence. 
 
 
 Fig. 18.  Analysis of the presence of the E7GGG insert by gel electrophoresis 
 
PCR analysis of E7GGG clones in the recombination pFP vector: 8 positive clones were 
positive out of 44.  
 
M, molecular weight marker, 100 bp 
C+, positive control (pFPE7) 
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Construction and selection of the viral recombinants 
 
The construction of the FPE6F47R and FPE7GGG viral recombinants was performed by IVR, 
whereas the selection of clones containing the heterologous gene was achieved by 
hybridization with a radiolabeled probe and the autoradiography (Fig. 19). Since the 
frequency of recombination between the FPwt virus and the recombination plasmid is very 
low, to the aim at obtaining a pure viral recombinant stock, plaque purification was 
performed by subsequent and repeated steps, to obtain a complete separation of the 
recombinant clones from the FPwt viruses. Viral clones were considered pure when the 
numbers of radiography-positive plaque were coincident with the plaque numbers 
originally present on the monolayer of infected cells.  
 
 
Fig. 19.  Plaque purification after in-vitro recombination 
 
Nitrocellulose membranes were hybridized with the radiolabeled probe. The different 
purification passages showing the increase of positive plaque numbers. 
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Different clones for each recombinant were amplified, titered and then analyzed to verify 
their ability to express the heterologous gene. The analyses were performed by different 
assays, starting from RT-PCR and then by Western blotting and immunofluorescence.  
 
 
FPE6F47R and FPE7GGG recombinants express the E6F47R and E7GGG mRNAs 
 
The transgene expression driven by the viral recombinants bearing E6F47R or E7GGG was 
first assessed by RT-PCR, performed on mRNA samples extracted from CEF, Vero and 
MRC-5 cells, previously infected with FPE6F47R or FPE7GGG. 
Agarose gel separation of the sequences amplified by RT-PCR highlighted the presence of 
specific 477-bp bands in samples infected with FPE6F47R (Fig. 20, Panel A), or 298-bp 
bands in samples infected with FPE7GGG (Fig. 20, Panel B). These bands were similar to 
those obtained in samples transfected with the expression plasmids, used as positive 
controls (C+). In particular, FPE6F47R showed a higher transcript level in human MRC-5 
cells than in permissive CEF cells or non-permissive Vero cells (Fig. 20, Panel A, lanes b). 
The intensity of the bands in FPE7GGG-infected samples was slightly higher in mammalian 
cells than in CEF cells (Fig. 20, Panel B, lanes d). No specific bands were amplified in 
mock-infected (Fig. 20, Panel B, lanes c) or FPwt-infected cells (Fig. 20, Panels A and B, 
lanes a), used as negative controls. 
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 Fig. 20.  Analysis of the transcript expression by FPE6F47R and  FPE7GGG recombinants 
 
RT-PCR amplification of E6F47R (A) and E7GGG (B) transcripts from cell lysates derived from 
different cell lines, infected with the viral recombinants. 
 
Mock-infected cells (lanes a); FPwt-infected cells (lanes c); FPE6F47R-infected cells (lanes b);  
FPE7GGG-infected cells (lanes d) 
M, molecular weight marker, 100 bp 
C+, positive control (pFPE6F47R (A) and pFPE7GGG (B)) 
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FPE6F47R and FPE7GGG recombinants express the respective 
heterologous proteins 
 
The correct expression of the heterologous E6F47R and E7GGG proteins was verified by 
Western blotting assays performed on cell lysates obtained from cells infected with the 
viral recombinants. 
The specific anti-E6 primary antibody, AbE6/Mu, allowed to detect a 19-kDa band 
representing the E6F47R protein (Fig. 21, Panel A, lanes 2, 4 and 6). The non-mutated E6 
protein (pE6), produced by an engineered bacterial vector, was used as a molecular 
weight control marker (Fig. 21, Panel A, lane 7). The E6F47R protein was expressed at 
higher levels by CEFs (5.8-fold) and Vero cells (4.4-fold) than by MRC-5 cells, as 
determined by densitometric analyses.   
Western blotting of FPE7GGG-infected cell lysates showed the presence of an 18-kDa band 
representing the mutated E7 oncoprotein (Fig. 21, Panel B, lanes 3 and 6). The non-
mutated E7 protein (pE7) produced by an engineered bacterial vector (Fig. 21, Panel B, 
lane 7) was used as a molecular weight control marker. CaSki cells (Fig. 21, Panel B, lane 
8) and CEFs and Vero cells infected with FPE7 were used as positive controls for the E7 
detection (Fig. 21, Panel B, lanes 1 and 4). It is worth noting that different monoclonal 
antibodies were used to determine the expression of these HPV proteins, and only some 
of them showed specificity and an adequate avidity in the different tests. In particular, the 
8C9 monoclonal antibody (Zymed) could not recognize the E7 protein produced by the 
FPE7GGG recombinant, which, conversely, was recognized by the ED17 monoclonal 
antibody (Santa Cruz Biotechnology), whereas a mixture of both (1:1) provided the best 
results.  
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FPE7 was always expressed at higher levels, when compared to FPE7GGG for the same 
cells, and the amount of E7GGG was 2.5-fold higher in Vero cells than in CEFs, as 
determined by densitometric analyses. No specific bands were seen when cells were 
infected with FPwt (Fig. 21, Panel A, lanes 1, 3 and 5; Panel B, lanes 2 and 5). 
 
 
 
 
 
Fig. 21.  Western blot analysis of the transgene expression by FPE6F47R and  FPE7GGG 
recombinants  
 
The heterologous gene expression was determined by identifying the E6F47R (A) or E7GGG (B) 
exogenous proteins on different cell lysates of FPE6F47R- or  FPE7GGG-infected cells 
 
A) lanes 1, 3 and 5  FPwt-infected cells  
lanes 2, 4 and 6  FPE6F47R-infected cells 
lane 7    E6 protein, C+ 
 
B) lanes 2 and 5   FPwt-infected cells  
lanes 3 and 6   FPE7GGG-infected cells 
lanes 1 and 4   FPE7-infected cells, C+ 
lane 7    E7 protein, C+ 
lane 8    CaSki cells, C+ 
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To verify the localization of the heterologous protein expressed by the two FP 
recombinants, immunofluorescence assays were carried out on CEFs, Vero and MRC-5 
cells depending on the viral recombinant.  
After FPE6F47R-infection, a granular fluorescence was detectable in CEFs and Vero and 
MRC-5 cells (Fig. 22, Panel A, 1b, 2b, 3b) using the AbE6/Gi mouse polyclonal antibody, 
with nuclear and perinuclear/cytoplasmic localization. No particular differences were seen 
in the different cell lines used during the assays. In fact, although Vero cells seem to be 
more fluorescent than other cell lines, they present a higher background fluorescence 
when infected with the empty vector. 
After FPE7GGG-infection, immunofluorescence was detectable only in Vero cells (Fig. 22, 
Panel B, 1b) using the rabbit polyclonal antibody, with nuclear/perinuclear/cytoplasmic 
localization and granular distribution.  
The FPE7-infected cells (Fig. 22, Panel B, 1c) used as a positive control showed a higher 
positivity, but no differences were seen in the cellular localization, although the 
fluorescence was more granular than in FPE7GGG-infected samples. 
FPwt-infected cells were always negative (Fig. 22; Panel A, 1a, 2a and 3a; Panel B, 1a), 
as expected. 
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 Fig. 22.  Analysis of the E6F47R (A) and E7GGG (B) proteins’ localization 
 
The expression and cellular localization of the heterologous E6F47R and E7GGG proteins were 
assessed by immunofluorescence performed on FPE6F47R- or FPE7GGG-infected cells (A and 
B, respectively). 
 
A) Panels 1a, 2a and 3a FPwt-infected cells, C- 
 Panels 1b, 2b and 3b FPE6F47R-infected cells 
 
B) Panel 1a  FPwt-infected cells, C- 
 Panel 1b  FPE7GGG-infected cells 
 Panel 1c  FPE7-infected cells, C+ 
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The E6- and E7-specific humoral responses are very low in vaccinated mice  
 
The immunized mice were tested for E6- and E7-specific humoral immunity to evaluate the 
ability of the different vaccine regimens to stimulate the production of antibodies and their 
capacity to recognize the HPV naïve oncogenic E6 and E7 proteins.  
ELISA, performed in plates coated with either the native purified recombinant pE6 protein 
or the CaSki cell lysates, allowed to measure the antibody response against E6. In the 
immune response protocol, the mice sera were collected before the first immunization 
(T0), and after the first and the last boosts (T2 and T3, respectively). The antibody 
responses against E6 were generally low (Fig. 23, Panel A), but they increased after the 
third immunization, although this effect was seen only when the assay was performed after 
plating CaSki cell lysates. In particular, a more evident increase occurred after the last 
boost in mice immunized twice with DNAE6F47R followed by a FPE6F47R boost (group 
GA.2). 
As for E7GGG, ELISA, using either plates coated with the purified recombinant pE7 protein 
or CaSki lysates, was performed to measure the specific anti-E7 antibody response in 
vaccinated mice. The sera of the immunized mice were collected after the first (T1) and 
third (T3) boosts and analyzed. Again, the antibody responses were generally low (Fig. 23, 
Panel B), but they increased after the third immunization when the assays were performed 
plating either the E7 protein or CaSki cell lysates. In particular, mice immunized only with 
the FPE7GGG (group GB.2) showed a higher antibody level after the last immunization, 
both when using pE7 or CaSki cell lysates, whereas mice that received the DNAE7GGG 
prime followed by FPE7GGG boosts (group GB.1) showed at T3 an increase, which was 
more evident when ELISA was performed using the E7 protein. The anti-E7 antibody 
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levels of mock-infected mice were lower when evaluated on the purified protein, whereas 
they showed an increase when assessed on CaSki cell lysates.   
Experiments using carbonate buffer or PBS as a coating buffer showed similar results 
(data not shown). 
 
 
 
Fig. 23.  Analysis of the anti-E6 and anti-E7 humoral responses 
 
The identification of the antibody responses against the E6 or E7 proteins induced by the two 
immune response protocols were assessed by ELISA after plating either the purified proteins 
or CaSki cell lysates. 
Data are expressed as means for each group of mice ± standard error. T0, T1, T2 and T3 
are the time of serum collection before or after mice immunization, depending on the vaccine 
protocol. 
 
A  E6F47R GA.1  DNA/FP/FP 
  GA.2  DNA/DNA/FP 
  GA.3  mock/mock/mock 
 
B  E7GGG GB.1  DNA/FP/FP/FP 
  GB.2  FP/FP/FP/FP 
  GB.3  mock/mock/mock/mock 
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Specific cell-mediated responses are observed in immunized vs mock-
vaccinated mice 
 
IFN-γ-secreting spot-forming cells (SFCs) were counted using splenocytes obtained after 
the last immunization of the immune response protocols. The analyses were performed 
with the aim at evaluating the ability of the immunization protocols to induce specific cell-
mediated immune responses. Data are presented as fold increases related to the 
responses obtained in cells stimulated with an unrelated protein. 
In animals immunized with the recombinants expressing the E6F47R gene, an increase in 
IFN-γ-producing cells was seen for both groups of vaccinated mice, above the level 
observed in the mock-vaccinated mice of protocol GA.3 (Fig. 24, Panel A). In particular, 
when the splenocytes were stimulated with the E6 protein, a significantly increased 
response was shown by protocol GA.1 (3.4-fold increase, p <0.001) and protocol GA.2 
(3.2-fold, p <0.001) vs GA.3. When the E6-specific aa 50-57 peptide was used, this 
increase was 6-fold higher for GA.1 (p <0.001) and 5.1-fold higher for GA.2 (p <0.01) than 
in GA.3. When the aa 18-26 peptide was used, a 11.5-fold increase for GA.1 (p <0.001) 
and 4.0-fold increase for GA.2 (p <0.05) vs GA.3 were observed. Statistical differences 
between the GA.1 and GA.2 vaccinated groups were seen only when the test was 
performed by stimulating cells with the aa 18-26 E6 peptide, showing a 2.9-fold increased 
response in GA.1 protocol (p<0.001) vs GA.2. 
Mice immunized with different recombinants expressing the E7GGG gene showed an 
increase in IFN-γ-producing cells in both GB.1 and GB.2 groups, above the level observed 
in the mock-vaccinated mice of group GB.3 (Fig. 24, Panel B). In particular, when 
splenocytes were stimulated with the E7-specific aa 49-57 peptide, which is associated to 
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the induction of CD8 precursors, protocols GB.1 and GB.2 showed a 15.6-fold (p<0.001) 
and 3.5-fold (p<0.05) increased response vs GB.3. When the E7-specific aa 30-67 peptide 
was used, which is associated to the induction of CD4 precursors, the increase was of 9.9-
fold for GB.1 (p<0.001) and 3.6-fold for GB.2 (p<0.05) vs GB.3. The comparison between 
the two different immunization protocols (GB.1 vs GB.2) highlighted a 4.45-fold (p<0.001) 
increased response when the stimulation was performed with the E7-specific aa 49-57 
peptide, and a 2.75-fold (p<0.001) increased response when the stimulation was 
performed with the E7-specific aa 30-67 peptide. Different epitope concentrations for CD4 
and CD8 gave similar results (data not shown). 
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Fig. 24.  Functional virus-specific T-cell responses to E6 or E7 
 
IFN-γ production was measured by ELISPOT assays after specific antigenic stimulation with 
the E6 protein or relative peptides (A) or with E7 peptides (B) to detect the cell-mediated 
immune responses. The number of IFN-γ-secreting spot-forming cells was assessed after 
subtracting the number of cells producing IFN-γ in the absence of stimulation. Data are 
presented as fold-increase responses to the specific protein or peptides, compared to 
responses to an unrelated protein, and they represent the means of all of the mice for each 
group ± standard error.  
 
A  E6F47R GA.1  DNA/FP/FP 
  GA.2  DNA/DNA/FP 
  GA.3  mock/mock/mock 
 
B  E7GGG GB.1  DNA/FP/FP/FP 
  GB.2  FP/FP/FP/FP 
  GB.3  mock/mock/mock/mock 
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Therapeutic immunization delays tumor growth 
 
After injecting the TC-1* cells into naïve mice, prime and boost immunizations were 
performed on days 3 and 10 p.c., respectively.  
When immunotherapeutic treatments were performed with recombinants expressing the 
E6F47R protein, the number of tumor-bearing animals was significantly lower in the 
immunized mice compared to the control group (Fig. 25, Panel A; GC.1, GC.2, GC.3 vs 
GC.4, p <0.001). In particular, tumor appearance was delayed to day 21 p.c. in 20% of the 
mice of GC.1 and GC.3, and to day 27 p.c. in 40% of the animals of group GC.2. Tumor 
development was seen in 80% of the mice at day 17 p.c. in group GC.4, and at day 34 and 
31 p.c. in groups GC.2 and GC.3. At day 54, only 20% of the animals of group GC.1 
developed tumors, whereas, cancer-bearing mice remained 80% in groups GC.2 and 
GC.3. The numbers of healthy mice remained higher in group GC.1, when compared to 
both groups GC.2 and GC.3. Statistical analyses also indicate a significant difference 
between group GC.2 vs GC.1 (p <0.05) and group GC.3 vs GC.1 (p <0.01). 
Also, mice treated with the different recombinants expressing the E7GGG gene showed a 
significant difference in the percentage of tumor-bearing animals among the three groups 
(Fig. 25, Panel B). In particular, a significant difference was found between groups GD.2 
vs GD.3 and GD.1 vs GD.2 (p<0.05 and p<0.01, respectively). Tumor appearance was 
delayed to day 23 p.c. in 40% and 33.3% of the mice of groups GD.3 and GD.1, 
respectively, whereas tumors were detectable earlier (day 16 p.c.) in 16.7% of the animals 
of group GD.2. Tumors developed in around 50% of the mice earlier in group GD.2 (day 
21 p.c.) and by day 27 p.c. in groups GD.3 and GD.1. By day 45, only in group GD.3 
tumors developed in 100% of the animals, whereas, by the same day, tumor-bearing mice 
were 50% in group GD.1 and 83.3% in group GD.2.  
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Fig. 25.  Tumor growth after the therapeutic immunization  
 
Mice were challenged with TC-1* cells and immunized at days 3 and 10 p.c. with the plasmid 
or viral immunogens expressing the E6F47R (A) or the E7GGG (B) genes. Tumor development 
was assessed by palpation and data are presented as the percentage of tumor-bearing mice 
after challenge. 
 
A  E6F47R GC.1  TC-1*/DNA/DNA 
  GC.2  TC-1*/DNA/ FP 
  GC.3  TC-1*/FP/FP 
  GC.4  TC-1*/mock/mock 
 
B  E7GGG GD.1  TC-1*/DNA/FP 
  GD.2  TC-1*/FP/FP 
  GD.3  TC-1*/mock/mock 
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DISCUSSION 
 
Prevention and therapy of HPV-related pathologies, such as cervical cancer, can be 
pursued both by prophylactic and therapeutic vaccines. Currently available vaccines, 
Gardasil® and Cervarix®, target L1 capsid protein of high risk HPV strains to prevent the 
viral infection, but they show some limitations due to their high-cost of production, and their 
restriction to only a few viral genotypes. At present, it is also impossible to determine their 
protective long-term durability and efficacy. 
Present scientific researches aim therefore at developing new low-cost production 
systems, as well as VLPs containing also the L2 capsid protein, which is more conserved 
among the different HPVs genotypes and presents a high number of cross-reactive 
epitopes [125]. Although current vaccines are able to protect healthy subjects from HPV 
infection, they cannot be effective to previously infected individuals, and thus, they are 
completely inadequate to treat already established lesions. Considering the high numbers 
of HPV-infected subjects and the time lag between infection and tumor appearance, the 
development of an effective therapeutic vaccine is a priority.   
These vaccines aim at inducing a complete response, in particular by simulating a cell-
mediated immunity against the early-expressed HPV antigens, such as the E6 and E7 
proteins, rather than against the capsid antigens. In fact, E6 and E7 proteins are 
constitutively expressed both in precancerous lesions and in already established HPV-
related cancers. New strategies involve the construction of chimeric VLPs containing both 
the L1 protein in association with E6 and E7 , with the aim at developing preventive and 
therapeutic vaccines in a single formulation [126]. 
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The aim of this project was the construction of new immunogens expressing genes coding 
for the mutated non-oncogenic forms of the HPV16 E6 and E7 proteins (E6F47R and E7GGG, 
respectively), the evaluation of their ability to induce a specific immune response in 
vaccinated mice and their therapeutic efficacy on a mouse model of cervical tumor. 
Modifications inside the gene sequences make these immunogens safer, since they are 
devoid of the oncogenic activity of the native protein forms. 
The E6F47R gene was cloned into the pFP recombination plasmid following different 
strategies. Some problems were encountered during the insertion of the heterologous 
gene into the intermediate and the final avian vectors. In fact, when the E6F47R gene was 
cut out from the original plasmid using specific restriction enzymes, both the subcloning 
and the final cloning were achieved easily, whereas, when the gene was amplified by 
PCR, cut with the appropriate restriction enzymes and purified, the ligation into the 
recombination plasmid did not occur. Although it is still unclear, we hypothesize that the 
ligation event might have been hampered by an incomplete digestion or by the purification 
process performed before the ligation. Although the direct insertion into pcDNA3 and pFP 
vectors was obtained easily, this strategy generated an exceeding 100-bp region between 
the promoter and the starting codon of the heterologous gene, which might have impaired 
the coding process. Thus, a parallel strategy was followed by cloning the E6F47R gene 
amplified by PCR without performing any enzymatic restriction reaction and purification 
before inserting the gene into the vector. This hypothesis was confirmed, as the gene was 
correctly cloned inside the intermediate vector and then into the final pFP recombination 
plasmid.  
Due to the similar size of the modified E6 and E7 genes, it still remains unclear why, 
following the same strategy of PCR amplification, the insertion problems have raised only 
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for E6F47R and not for E7GGG. Even if the amplification strategy by PCR allows the 
preparation of more precise constructs, it seems to be less efficient when a subsequent 
cloning has to be performed. However, it represents a valid strategy, which might be 
dependent on the restriction enzyme used or on the restriction site in the flanking regions. 
To the aim at generating a recombinant vaccine able to induce a specific immune 
response, and therefore with a preventive and therapeutic efficacy, it is necessary that the 
heterologous gene inserted into the vector is correctly expressed and presented to the 
immune system. To this purpose, the expression of the exogenous genes inserted in the 
FPE6F47R and FPE7GGG viral recombinants was evaluated, by analyzing the presence of 
the specific transcripts by RT-PCR and then by verifying the synthesis of the 
corresponding protein by Western blotting and immunofluorescence. 
The RNA extracted from CEF, Vero and MRC-5 cells infected with FPE6F47R or FPE7GGG 
recombinants showed the presence of specific transcripts in all of the cell lines, with a 
slightly higher levels in human MRC-5 cells. Thus, the insertion of the mutated forms of the 
heterologous genes do not interfere with their expression in the different cell lines, 
although it seems that expression is better in human cells, where the viral replication cycle 
is abortive. 
Although the amounts of the E6F47R transcripts expressed by FPE6F47R were similar in all 
of the cell lines, Western blotting showed a different protein expression level. This cannot 
be ascribed to a lower efficiency of the E6F47R gene expression by the FP vector, as 
protein expression was evident in all of the infected cells assessed by 
immunofluorescence. In CEF, as well as in the positive control, an extra-band was seen, 
also described in other studies [127,128]. Although this might be due to an already 
observed splicing process [129], this cannot be the case of FP viruses that replicate in the 
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cytoplasm. The presence of an additional ATG, downstream the initial starting codon [127], 
can in fact result in the synthesis of a lower-MW E6 (151 aa, around 18 kDa) in some cell 
lines, such as in CaSki cells, besides the full length E6 protein (158 aa, around 19 kDa).  
Similarly, the amount of E7GGG RNA after FPE7GGG infection was comparable in CEF, Vero 
and MRC-5 cells, showing only slight differences, whereas by Western blotting a 2.5-fold 
lower protein expression was seen in CEF, which can be explained by the complete 
replicative cycle and cytopathic effect of the vector in these cells. A 7.2- and 2.2-fold 
higher expression was also shown in CEF and Vero cells infected with FPE7 over the 
mutated FPE7GGG recombinant. This has not been described previously using recombinant 
plasmids [96] or plant-produced vaccines [130], and it might therefore be ascribed to the 
lower efficiency of E7GGG gene expression by the FP vector. Unexpectedly, protein 
detection by Western blotting using a mixture of the anti-E7 ED17 and 8C9 monoclonal 
antibodies recognized both the native and the mutated proteins, whereas the 8C9 
monoclonal antibody alone only recognized the non-denatured protein. Although we do not 
have an explanation for this discrepancy, if this was due to the disruption of a 
conformational site by substituting the GLYGYG motif for the DLYCYE sequence [96], the 
E7GGG recognition by the ED17 monoclonal antibody alone should occur equally also when 
used alone, and not only when used with 8C9. The difficulty of E7GGG recognition by the 
monoclonal antibodies was also observed when assessed by immunofluorescence, where, 
in contrast to what already reported [131], the separate or mixed monoclonal antibodies 
did not bind the native E7 and mutated E7GGG proteins, which were recognized only by the 
rabbit polyclonal antibody developed in our laboratory. 
The antibody responses against the E6 protein, which were evaluated by ELISA (E6F47R 
immune response protocol), were detectable only after the third immunization in the 
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animals following the DNA/DNA/FP protocol (GA.2) and when using the CaSki cell lysates. 
At present, we have no explanation for the different recognition of the E6 antigen produced 
in its native form by E. coli or by CaSki cells, although this has already been reported for 
the responses against E6 and E7 produced in the same way [132]. Conversely, the 
numbers of IFN-γ-secreting cells were significantly higher after immunization with the 
E6F47R recombinants, which are essential in clearing TC-1* tumor cells, and can overcome 
the lack of anti-E6 antibody response. Surprisingly, although the aa 18-26 subdominant 
epitope may contribute only slightly to the antitumor effect [122], a higher response by the 
IFN-γ-producing splenocytes was detected to this peptide in the DNA/FP/FP vs 
DNA/DNA/FP (GA.1 vs GA.2) immunization protocol. HPV16 E6 epitope mapping [133] 
revealed that the aa 50-57 region represents the minimal core sequence essential for E6-
specific CTL activity, and that the aa 48-57 peptide is the optimal immunodominant 
sequence. The E6 aa 50-57 deletion prevented protection of TC-1-challenged mice from a 
DNA vaccine [121,134], and it is to be noted that the E6 aa 48-57 peptide contains CTL 
epitopes that are presented by E6-expressing TC-1 cells. Although it has still not been 
determined which HLA-A24-restricted epitope is the most immunogenic one and the most 
suitable for immunotherapy, a novel potent HPV16 E6 aa 66-74 peptide has recently been 
reported, that can be used in vitro as an efficient means of CTL induction [134] to 
discriminate between the different immunization regimens. 
As for the E6F47R protocol, sera collected from mice and immunized with recombinants 
expressing the E7GGG gene (immune response protocol) showed a low antibody response 
after ELISA analyses, which only increased slightly over time and might be ascribed to the 
inadequate antibody affinity and/or avidity. However, the numbers of IFN-γ-secreting cells 
showed a limited increase after FPE7GGG priming (GB.2 group), but became higher when 
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priming was performed with DNAE7GGG (GB.1 group). A reduction in the antiviral IFN-γ 
response has already been shown for vaccinia and other mammalian poxviruses [135] that 
express genes mimicking the IFN-γ receptor, but this is unlikely for FP-based vectors that 
do not replicate in mammalian cells, and has never been described in FP-immunized 
animals [113]. To better define the specific induction of IFN-γ-secreting cells, other highly 
stimulatory antigens like OVA could be used, although other authors have already 
demonstrated that HPV E7 and OVA generate comparable results on T-cell response [55]. 
Finally, therapeutic immunization protocols using recombinants expressing the E6F47R or 
E7GGG genes were administered to mice previously challenged with TC-1* cells with the 
aim at evaluating the therapeutic efficacy of the different regimens. 
After the therapeutic immunization with the recombinants expressing the E6F47R gene, 
tumor growth was delayed in mice of all the E6F47R-immunized groups with 80% of still-
healthy animals at 21 days p.c., when 100% of the mock-infected control animals showed 
tumor development. In particular, the numbers of healthy animals remained higher after 
the DNA/DNA protocol, which should therefore be considered the most effective regimen 
in mice. However, although genetic vaccination has emerged as an attractive strategy for 
immunotherapy, in studies performed in non-human and human primates, DNA vaccines 
suffered from low immunogenicity and efficacy. Previous studies have also demonstrated 
that higher protection can be obtained when animals are primed with recombinant DNA 
followed by recombinant FP boost than when using FP recombinants alone [79,120]. In the 
present project, both DNA/FP and FP/FP prime/boost immunization regimens were tested 
for the therapeutic immunization and a difference was noted between groups immunized 
with DNA/FP rather than FP/FP. This suggests that DNA prime followed by the FP boost 
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can be a more promising strategy to induce CTLs, kill tumor cells, and be effective in 
eliciting anti-tumor immune responses in humans. 
After therapeutic immunization using the recombinants expressing the E7GGG gene on 
previously TC-1*-challenged mice, tumor development was delayed in DNA/FP immunized 
mice compared to those immunized twice with FP, with 50% of still-healthy animals 45 
days p.c., whereas all of the mock-infected animals of the control group showed greater 
tumor development and a lower survival. Since Kaplan–Meier analysis did not indicate a 
significant statistical difference among the groups, it is not possible to exclude any random 
effect of the assay unless a higher number of animals is used. Although the use of a FP 
vector with unrelated antigens could be a more appropriate control, the experiment was 
repeated twice with similar results. This suggests that DNA prime followed by the FP boost 
can be a promising strategy, as FPE7 recombinants might better induce CTLs, which can 
destroy the tumor cells, and be more effective in eliciting anti-tumor immune responses in 
humans. 
Many HPV vaccine strategies have focused on eliciting HPV E6/E7-specific T-cell 
responses, and several vaccination trials have been performed on patients with cervical 
cancer, genital warts and papillomas [136,137] using E6/E7 proteins, DNA or viral vectors 
carrying the E6/E7 oncogenes or their variants. Studies are also ongoing to improve 
antigen processing and presentation [138,139]. In this context, a partial tumor regression 
was obtained in the rabbit model by VSV-based vaccines encoding the E6 or UbE6 
[140,141] and a potent antitumor effect was induced by administering mice with DNA 
vaccines encoding HPV16 E6, E7 and L2 proteins fused to calreticulin (CRT) [139]. Some 
of these vaccines, as CRT/E7(detox) and VGX-3100 [142], are also in clinical trial. 
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However, vaccines expressing the E6 gene alone have not previously been tested for 
therapeutic efficacy in prime/boost protocols.  
Several therapeutic vaccination trials have also been performed on patients with cervical 
cancer, genital warts and papillomas [136,137] using the HPV16 E7 protein, DNA or viral 
vectors carrying the E7 oncogene or its variants. However, in spite of the immune 
responses, the expected efficacy was often low, suggesting that other effects have to be 
elicited by therapeutic vaccines, using adjuvants, innate immunity stimulation, or Treg 
depletion [143]. Vaccination with VV recombinants expressing the E7 oncogene elicited a 
strong response and has proven to be well tolerated in animal and human trials. These 
recombinants have promoted tumor regression in patients with advanced cervical cancer, 
which was sustained by the induction of CTLs specifically directed against infected cells 
[78,144]. 
Due to their natural host-range restriction to avian species [145,106], correct expression of 
transgenes in mammalian cells, and ability to elicit a complete immune response in 
vaccinated hosts [146], FP recombinants, which were used as vectors in this project, might 
represent alternative and safer immunogens to VV, which causes lytic infection, 
ulcerations, and scab formation. Moreover, the use of FP recombinants, combined or not 
with DNA in a prime-boost immunization regimens, has already shown higher protection 
when mice were primed with DNA followed by an FP boost [120].  
In conclusion, during this project we demonstrated that: (i) FPE6F47R and FPE7GGG can 
correctly express the E6F47R and E7GGG proteins, respectively; (ii) anti-E6- and anti-E7-
specific antibodies can be detected by ELISA, although at low levels, after mice 
immunization using recombinant E6 or E7 proteins or CaSki cell lysates as plated 
antigens; (iii) specific increase in IFN-γ-producing cell responses are induced in mice as 
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verified by the immune response protocols; (iv) after therapeutic immunization, the 
numbers of tumor-bearing mice are lower when the heterologous prime-boost regimens 
are used. 
As future perspectives, results obtained during this project could represent a starting point 
to improve the development of an effective preventive/therapeutic vaccine to control HPV-
related cervical cancers. In particular, the introduction of further modifications into the 
sequences of the E6 and E7 genes, such as their fusion with the Coat Protein derived from 
the Potato virus X, as well as the combined use of the two proteins into the same 
immunization regimen, could improve the immunogenicity, and thus the efficacy of future 
vaccines. 
 
 
 
 
 
 
 
 
 
 
91 
 
REFERENCES 
 
1. Burd, E. M. 2009. Human papillomavirus and cervical cancer. Clinical Microbiology Reviews 
16:1-17. 
 
2. Zur Hausen, H. 1996. Papillomavirus infections-a major cause of human cancers. Biochimica 
et Biophysica Acta 1288:F55-F78. 
 
3. Zur Hausen, H. 2000. Papillomaviruses causing cancer: evasion from host cell control in 
early events in carcinogenesis. J. Natl. Cancer Inst. 92:690-698. 
 
4.  De Villiers, E.-M., Fauquet, C., Broker, T. R., Bernard, H.-U. & zur Hausen, H. 2004. 
Classification of papillomaviruses. Virology. 324:17–27. 
 
5. Walboomers, J. M., M. V. Jacobs, M. M. Manos, X. Bosch, J. A. Kummer, K. V. Shah, P. J. 
Snjders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary 
cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19. 
 
6. Zur Hausen, H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. 
Nat. Rev. Cancer. 2:342-350. 
 
7. Kjellberg, L., G. Hallmans, A. M. Ahren, R. Johansson, F. Bergman, G. Wadell, T. Angstrom, 
and J. Dillner. 2000. Smoking, diet, pregnancy and oral contraceptive use as risk factors for 
cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br. J. Cancer. 
82:1332-1338. 
 
8. Howley, P. M. and D. R. Lowy. 2007. Papillomaviruses, p. 2299-2354. In: D. M. Knipe and P. 
M. Howley (eds.), Fields Virology. Fifth ed., vol. 2. Wolters Kluver, Lippincott Williams & 
Wilkins, Philadelphia. 
 
9. Hsueh, P. R. 2009. Human papillomavirus, genital warts, and vaccines. J. Microbiol. 
Immunol. Infect. 42:101-106. 
 
10. Zhang, B., Spandau, D. F. and Roman, A. 2002. E5 protein of human papillomavirus type 16 
protects human foreskin keratinocytes from UV B-irradiation-induced apoptosis. Journal of 
Virology. 76:220–231.  
 
11.  Stanley, M. 2008. Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109:S15-S21.  
 
12. Hummel, M., J. B. Hudson, and L. A. Laimins. 1992. Differentiation induced and constitutive 
transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 
66:6070-6080.  
 
13. Jones, D. L. and K. Munger. 1996. Interactions of the human papillomavirus E7 protein with 
cell cycle regulators. Semin. Cancer Biol. 7:327-337.  
 
14. Pyeon, D., S. M. Pearce, S. M. Lank, P. Ahlquist, and P. F. Lambert. 2009. Establishment of 
human papillomavirus infection requires cell cycle progression. PLoS Pathogens 5.  
92 
 
 
15. Kanodia, S., Fahey, L. M. and Kast, W. M. 2007. Mechanisms used by human 
papillomaviruses to escape the host immune response. Current Cancer Drug Targets. 
7(1):79–89,. 
 
16.  Stanley, M. 2006. Immune responses to human papillomavirus. Vaccine. 24( 1):16–22. 
 
17. Doorbar, J. 2005. The papillomavirus life cycle. Journal of Clinical Virology. 32:S7–S15. 
 
18. Martinez, F. O., Helming, L. and Gordon, S. 2009. Alternative activation of macrophages: an 
immunologic functional perspective. Annual Review of Immunology. 27:451–483, 2009.  
 
19. Mazibrada, J., Rittà, M., Mondini M., et al. 2008. Interaction between inflammation and 
angiogenesis during different stages of cervical carcinogenesis. Gynecologic Oncology. 108: 
112–120. 
 
20. Clerici, M., Merola, M., Ferrario E., et al. 1997. Cytokine production patterns in cervical 
intraepithelial neoplasia: association with human papillomavirus infection. Journal of the 
National Cancer Institute. 89: 245–250. 
 
21. Peghini, B. C., Abdalla, D. R., Barcelos, A. C., Teodoro, L.,  Murta, E. F. and Michelin M. A. 
2012. Local cytokine profiles of patients with cervical intraepithelial and invasive neoplasia. 
Human Immunology. 73: 920–926. 
 
22. Vambutas, A., DeVoti, J., Pinn, W., Steinberg, B. M. and Bonagura, V. R. 2001. Interaction of 
human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-
dependent peptide transport. Clinical Immunology. 101: 94–99. 
 
23. Keating, P. J., Cromme, F. V., Duggan-Keen M. et al. 1995. Frequency of down-regulation of 
individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression. British 
Journal of Cancer. 72: 405–411. 
 
24. Campo, M. S., Graham, S. V., Cortese M. S. et al. 2010. HPV-16 E5 down-regulates 
expression of surface HLA class I and reduces recognition by CD8 T cells. Virology.  
407:137–142. 
 
25. Vousden, K. H. 1993. Interactions of human papillomavirus transforming proteins with the 
products of tumor suppressor genes. FASEB J. 7:872-879.  
 
26. Villa, L. L. 2006. Biology of genital human papillomaviruses. Inter. J. of Ginecology and 
Obstetrics 94:53-57.  
 
27. Guccione, E., P. Massimi, A. Bernat, and L. Banks. 2002. Comparative analysis of the 
intracellular location of the high- and low- risk human papillomavirus oncoproteins. Virology 
293:20-25.  
 
28. Munger, K., W. C. Phelps, V. Bubb, P. M. Howley, and R. Schlegel. 1989. The E6 and E7 
genes of the human papillomavirus type 16 together are necessary and sufficient for 
transformation of primary human keratinocytes. J. Virol. 63:4417-4421.  
 
29. Weintraub, S. J., K. N. Chow, R. X. Luo, S. H. Zhang, S. He, and D. C. Dean. 1995. 
Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 
375:812-815.  
 
93 
 
30. Munger, K. and P. M. Howley. 2002. Human papillomavirus immortalization and 
transformation functions. Virus Res. 89:213-228.  
 
31. Jo, H. and J. W. Kim. 2009. Implications of HPV infection in uterine cervical cancer. Cancer 
Ther. 3:419-434.  
 
32. Nguyen, C. L. and K. Munger. 2008. Direct association of the HPV16 E7 oncoprotein with 
cyclin A/CDK2 and cyclin E/CDK2 complexes. Virology 380:21-25.  
 
33. Zwerschke, W. and P. Jansen-D rr. 2000. Cell transformation by the E7 oncoprotein of 
human papillomavirus type 16: interactions with nuclear and cytoplasmic target proteins. Adv. 
Cancer Res. 78:1-29.  
 
34. Ko, L. and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054-1072.  
 
35. Huibregtse, J. M., M. Scheffner, and P. M. Howley. 1991. A cellular protein mediates 
association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J. 
10:4129-4135.  
 
36. Longworth, M. S. and L. A. Laiminis. 2004. Pathogenesis of human papillomaviruses in 
differentiating epithelia. Microbiol. Mol. Biol. Rev. 68:362-372.  
 
37. Massimi, P., N. Gammoh, M. Thomas, and L. Banks. 2004. HPV E6 specifically targets 
different cellular pools of its PDZ domaincontaining tumour suppressor substrates for 
proteasome-mediated degradation. Oncogene 23:8033-8039.  
 
38. Lee, S. S., B. Glaunsinger, F. Mantovani, L. Banks, and R. T. Javier. 2000. Multi-PDZ domain 
protein MUPP1 is a cellular target for both adenovirus E4- ORF1 and high-risk papillomavirus 
type 18 E6 oncoproteins. J. Virol. 74:9680-9693.  
 
39. Von Knebel Doeberitz, M. 2002. New markers for cervical dysplasia to visualise the genomic 
chaos created by aberrant oncogenic papilloma virus infections. Eur. J. Cancer 38:2229-
2242.  
 
40. Klingelhutz, A. J., S. A. Foster, and J. K. McDougall. 1996. Telomerase activation by the E6 
gene product of human papillomavirus type 16. Nature 380:79-82.  
 
41. Cheng, S., D. Schmidt-Grimminger, T. Murant, T. Broker, and L. Chow. 1995. Differentiation-
dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA 
replication in suprabasal differentiated keratinocytes. Genes Dev. 9:2335-2349.  
 
42. Nelson, L. M., R. C. Rose, and J. Moroianu. 2002. Nuclear import strategies of high risk 
HPV16 L1 major capsid protein. J. Biol. Chem. 277:23958-23964.  
 
43. Noad, R. and P. Roy. 2003. Virus-like particles as immunogens. Trends Microbiol. 11:238-
244.  
 
44. Schiller, J.T., Castellsague, X., Villa, L.L., Hildesheim, A. 2008. An update of prophylactic 
human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 26-10:K53-
61. 
 
45. Villa, L.L., Costa, R.L., Petta, C.A., et al. 2005. Prophylactic quadrivalent human 
papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a 
94 
 
randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 
6:271-8. 
 
46. Paavonen, J., Jenkins, D., Bosch, F.X., et al. 2007. Efficacy of a prophylactic adjuvanted 
bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 
and 18 in young women: an interim analysis of a phase III double-blind, randomised 
controlled trial. Lancet. 369:2161-70. 
 
47. Draper, E., Bissett, S.L., Howell-Jones, R., et al. 2013. A randomized, observer-blinded 
immunogenicity trial of Cervarix((R)) and Gardasil((R)) human papillomavirus vaccines in 12-
15 year old girls. PLoS One. 8:e61825. 
 
48. Griffin, H., Elston, R., Jackson, D., Ansell, K., Coleman, M., Winter, G., Doorbar, J.. 2006. 
Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J 
Mol Biol. 355:360–378.  
 
49. Accardi, L., Donà, M.G., Di Bonito, P., Giorgi, C. 2005. Intracellular anti-E7 human antibodies 
in single-chain format inhibit proliferation of HPV16-positive cervical carcinoma cells. Int J 
Cancer. 116:564–570. 
 
50. Accardi, L., Paolini, F., Mandarino, A., Percario, Z., Bonito, P.D., Carlo, V.D., Affabris, E., 
Giorgi, C., Amici, C., Venuti, A. 2013. In vivo antitumor effect of an intracellular single-chain 
antibody fragment against the E7 oncoprotein of Human Papillomavirus 16. Int J Cancer.  
 
51. Badaracco, G., Venuti, A. 2007. Human papillomavirus therapeutic vaccines in head and 
neck tumors.Expert Rev Anticancer Ther. 7:753–766.  
 
52. Richter, C.E., Cocco, E., Bellone, S., Bellone, M., Casagrande, F., Todeschini, P., Rüttinger, 
D., Silasi, D.A., Azodi, M., Schwartz, P.E., Rutherford, T.J., Pecorelli, S., Santin, A.D. 2010. 
Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) 
and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-
EpCAM antibody. Int J Gynecol Cancer. 20:1440–1447.  
 
53. Stewart, T.J., Drane, D., Malliaros, J. 2004.  ISCOMATRIX adjuvant: an adjuvant suitable for 
use in anticancer vaccines. Vaccine. 22:3738–3743.  
 
54. Cui, Z., Huang, L. 2005. Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant 
for proteinbased vaccines: therapeutic effect against cervical cancer. Cancer Immunol 
Immunother. 54:1180–1190.  
 
55. Kang, T.H., Monie, A., Wu, L.S. 2011. Enhancement of protein vaccine potency by in vivo 
electroporation mediated intramuscular injection. Vaccine. 29:1082–1089.  
 
56. Zwaveling, S., Ferreira Mota, S.C., Nouta, J. 2002. Established human papillomavirus type 
16-expressing tumors are effectively eradicated following vaccination with long peptides. J 
Immunol. 169:350–358. 
 
57. Zhang, Y.Q., Tsai, Y.C., Monie, A., Hung, C.F., Wu, T.C. 2010. Carrageenan as an adjuvant 
to enhance peptide-based vaccine potency. Vaccine. 28:5212–5219.  
 
58. Wu, C.Y., Yang, H.Y., Monie, A. 2011. Intraperitoneal administration of poly (I:C) with 
polyethylenimine leads to significant antitumor immunity against murine ovarian tumors. 
Cancer Immunol Immunother. 60:1085–1096.  
 
95 
 
59. Lin, K., Roosinovich, E., Ma, B., Hung, C.F., Wu, T.C. 2010. Therapeutic HPV DNA vaccines. 
Immunol Res. 47:86–112.  
 
60. Venuti, A., Massa, S., Mett, V., Vedova, L.D., Paolini, F., Franconi, R., Yusibov, V. 2009. An 
E7-based therapeutic vaccine protects mice against HPV16 associated cancer. Vaccine. 
27:3395–3397.  
 
61. Massa, S., Simeone, P., Muller, A., Benvenuto, E., Venuti, A., Franconi, R. 2008. Antitumor 
activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused 
to a plant virus coat protein. Hum Gene Ther. 19:354–364.  
 
62. Massa, S., Paolini, F., Spanò, L., Franconi, R., Venuti, A. 2011. Mutants of plant genes for 
developing cancer vaccines. Hum Vaccin. 7(Suppl147):55.  
 
63. Klencke, B., Matijevic, M., Urban, R.G., Lathey, J.L., Hedley, M.L., Berry, M., Thatcher, J., 
Weinberg, V., Wilson, J., Darragh, T., Jay, N., Da Costa, M., Palefsky, J.M. 2002. 
Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal 
dysplasia: a phase I study of ZYC101. Clin Cancer Res. 8:1028–1037.  
 
64. Sheets, E.E., Urban, R.G., Crum, C.P., Hedley, M.L., Politch, J.A., Gold, M.A., Muderspach, 
L.I., Cole, G.A., Crowley-Nowick, P.A. 2003. Immunotherapy of human cervical high-grade 
cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 
plasmid DNA. Am J Obstet Gynecol. 188:916–926.  
 
65. Garcia, F., Petry, K.U., Muderspach, L., Gold, M.A., Braly, P., Crum, C.P., Magill, M., 
Silverman, M., Urban, R.G., Hedley, M.L., Beach, K.J. 2004. ZYC101a for treatment of high-
grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 
103:317–326.  
 
66. Souders, N.C., Sewell, D.A., Pan, Z.K., Hussain, S.F., Rodriguez, A., Wallecha, A., Paterson, 
Y. 2007. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8 + T 
cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer 
Immun. 7:2. 
 
67. Sewell, D.A., Pan, Z.K., Paterson, Y. 2008. Listeria-based HPV-16 E7 vaccines limit 
autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. 
Vaccine. 26:5315–5320.  
 
68. Quistian-Martinez, D., Villatoro-Hernandez, J., Loera-Arias, M.J., Rangel-Colmenero, B.R., 
Zavala-Flores, L.M., Sepúlveda-Saavedra, J., Guzmán-López, S., Elizondo-Omaña, R.E., 
Montes-de-Oca-Luna, R., Saucedo-Cárdenas, O. 2010. Efficient secretion of a modified E7 
protein from human papilloma virus type-16 by Lactococcus lactis. Lett Appl Microbiol. 
51:383–387. 
 
69. Adachi, K., Kawana, K., Yokoyama, T., Fujii, T., Tomio, A., Miura, S., Tomio, K., Kojima, S., 
Oda, K., Sewaki, T., Yasugi, T., Kozuma, S., Taketani, Y. 2010. Oral immunization with a 
Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an 
effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine. 
28:2810–2817. 
 
70. Lee, D.W., Anderson, M.E., Wu, S., Lee, J.H. 2008. Development of an adenoviral vaccine 
against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer. 
Arch Otolaryngol Head Neck Surg. 134:1316–1323.  
 
96 
 
71. Gomez-Gutierrez, J.G., Elpek, K.G., Montes De Oca-Luna, R., Shirwan, H., Sam Zhou, H., 
McMasters, K.M. 2007. Vaccination with an adenoviral vector expressing calreticulin-human 
papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. 
Cancer Immunol Immunother. 56:997–1007.  
 
72. Daemen, T., Riezebos-Brilman, A., Regts, J., Dontje, B., van der Zee, A., Wilschut, J. 2004. 
Superior therapeutic efficacy of alpha virus mediated immunization against human papilloma 
virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir 
Ther. 9:733–742.  
 
73. Cassetti, M.C., McElhiney, S.P., Shahabi, V., Pullen, J.K., Le Poole, I.C., Eiben, G.L., Smith, 
L.R., Kast, W.M. 2004. Antitumor efficacy of Venezuelan equine encephalitis virus replicon 
particles encoding mutated HPV16 E6 and E7 genes. Vaccine. 22:520–527.  
 
74. Velders, M.P., McElhiney, S., Cassetti, M.C., Eiben, G.L., Higgins, T., Kovacs, G.R., 
Elmishad, A.G., Kast, W.M., Smith, L.R. 2001. Eradication of established tumors by 
vaccination with Venezuelan equine encephalitis virus replicon particles delivering human 
papillomavirus 16 E7 RNA. Cancer Res. 61:7861–7867. 
 
75. Hibbitts, S. 2010. TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 
L2E6E7) for the potential treatment of HPV16-associated genital diseases. Curr Opin Mol 
Ther. 12:598–606.  
 
76. Zurkova, K., Babiarova, K., Hainz, P., Krystofova, J., Kutinova, L., Otahal, P., Nemeckova, S. 
2009. The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus 
enhances immunogenicity of the vector. Oncol Rep. 21:1335–1343.  
 
77. Hsieh, C.J., Kim, T.W., Hung, C.F., Juang, J., Moniz, M., Boyd, D.A., He, L., Chen, P.J., 
Chen, C.H., Wu, T.C. 2004. Enhancement of vaccinia vaccine potency by linkage of tumor 
antigen gene to gene encoding calreticulin. Vaccine. 22:3993–4001. 
 
78. Borysiewicz, L.K., Fiander, A., Nimako, M., Man, S., Wilkinson, G.W., Westmoreland, D., 
Evans, A.S., Adams, M., Stacey, S.N., Boursnell, M.E., Rutherford, E., Hickling, J.K., Inglis, 
S.C. 1996. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 
and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1523–1527.  
 
79. Radaelli, A., De Giuli Morghen, C., Zanotto, C., Pacchioni, S., Bissa, M., Franconi, R., Massa, 
S., Paolini, F., Muller, A., Venuti, A. 2012. A prime/boost strategy by DNA/fowlpox 
recombinants expressing a mutant E7 protein for the immunotherapy of HPV-associated 
cancers. Virus Res. 170:44–52.  
 
80. Davidson, E.J., Boswell, C.M., Sehr, P., Pawlita, M., Tomlinson, A.E., McVey, R.J., Dobson, 
J., Roberts, J.S., Hickling, J., Kitchener, H.C., Stern, P.L. 2003. Immunological and clinical 
responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus 
encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63:6032–6041.  
 
81. Baldwin, P.J., van der Burg, S.H., Boswell, C.M., Offringa, R., Hickling, J.K., Dobson, J., 
Roberts, J.S., Latimer, J.A., Moseley, R.P, Coleman, N., Stanley, M.A., Sterling, J.C. 2003. 
Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination 
for vulval and vaginal intraepithelial neoplasia. Clin Cancer Res. 9:5205–5213.  
 
82. Kaufmann, A.M., Stern, P.L., Rankin, E.M., Sommer, H., Nuessler, V., Schneider, A., Adams, 
M., Onon, T.S., Bauknecht, T., Wagner, U., Kroon, K., Hickling, J., Boswell, C.M., Stacey, 
S.N., Kitchener, H.C., Gillard, J., Wanders, J., Roberts, J.S., Zwierzina, H.  2002. Safety and 
97 
 
immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human 
papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical 
cancer. Clin Cancer Res. 8:3676–3685.  
 
83. Tseng, C.W., Trimble, C., Zeng, Q., Monie, A., Alvarez, R.D., Huh, W.K., Hoory, T., Wang, 
M.C., Hung, C.F., Wu, T.C. 2009. Low-dose radiation enhances therapeutic HPV DNA 
vaccination in tumor-bearing hosts.Cancer Immunol Immunother. 58:737–748.  
 
84. Kang, T.H., Lee, J.H., Song, C.K., Han, H.D., Shin, B.C., Pai, S.I., Hung, C.F., Trimble, C., 
Lim, J.S., Kim, T.W., Wu, T.C. 2007. Epigallocatechin-3-gallate enhances CD8 + T cell-
mediated antitumor immunity induced by DNA vaccination. Cancer Res. 67:802–811.  
 
85. Tseng, C.W., Hung, C.F., Alvarez, R.D., Trimble, C., Huh, W.K., Kim, D., Chuang, C.M., Lin, 
C.T., Tsai, Y.C., He, L., Monie, A., Wu, T.C. 2008. Pretreatment with cisplatin enhances E7-
specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer 
Res. 14:3185–3192.  
 
86. Tseng, C.W., Monie, A., Wu, C.Y., Huang, B., Wang, M.C., Hung, C.F., Wu, T.C. 2008. 
Treatment with proteasome inhibitor Bortezomib enhances antigen-specific CD8+ T-cell-
mediated antitumor immunity induced by DNA vaccination. J Mol Med. 86:899–908 
 
87. Zeng, Q., Peng, S., Monie, A., Yang, M., Pang, X., Hung, C.F., Wu, T.C. 2011. Control of 
cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV 
vaccination and vascular disrupting agents. Hum Gene Ther. 22:809–819.  
 
88. Peng, S., Monie, A., Pang, X., Hung, C.F., Wu, T.C. 2011. Vascular disrupting agent DMXAA 
enhances the antitumor effects generated by therapeutic HPV DNA vaccines. J Biomed Sci. 
18:21.  
 
89. Cao, Y., Zhao, J., Yang, Z., Cai, Z., Zhang, B., Zhou, Y., Shen, G.X., Chen, X., Li, S., Huang, 
B. 2010. CD4+FOXP3+ regulatory T cell depletion by low-dose cyclophosphamide prevents 
recurrence in patients with large condylomata acuminata after laser therapy. Clin Immunol. 
136:21–29.  
 
90. Bae, S.H., Park, Y.J., Park, J.B., Choi, Y.S., Kim, M.S., Sin, J.I. 2007. Therapeutic synergy of 
human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal 
involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in 
therapeutic synergy. Clin Cancer Res. 13:341–349.  
 
91. Butz, K., T. Ristriani, A. Hengstermann, C. Denk, M. Scheffner, and F. Hoppe-Seyler. 2003. 
siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive 
cancer cells. Oncogene 22:5938-5945.  
 
92. Courtete, J., A. P. Sibler, G. Zeder-Lutz, D. Dalkara, M. Oulad-Abdelghani, and G. Zuber. 
2007. Suppression of cervical carcinoma cell growth by intracytoplasmic codelivery of anti-
oncoprotein E6 antibody and small interfering RNA. Mol. Cancer Ther. 6:1728-1735.  
 
93. Ristriani, T., S. Fournane, G. Orfanoudakis, and M. Masson. 2009. A single-codon mutation 
converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-
dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene 28:762-772.  
 
94. Nominé, Y., M. Masson, S. Charbonnier, K.  Zanier, T. Ristriani, F. Deryckère, A.P. Sibler, D.  
Desplancq, R.A. Atkinson, E. Weiss, G. Orfanoudakis, B. Kieffer, G. Travé. 2006. Structural 
98 
 
and functional analysis of E6 oncoprotein: insights in the molecular pathways of human 
papillomavirus-mediated pathogenesis. Mol Cell. 21:665-78 
 
95. Nominé, Y., T. Ristriani, C. Laurent, J.F. Lefèvre, E. Weiss, G. Travé. 2001. A strategy for 
optimizing the monodispersity of fusion proteins: application to purification of recombinant 
HPV E6 oncoprotein. Protein Eng. 14:297-305 
 
96. Smahel, M., P. Síma, V. Ludvíkova, V. Vonka. 2001. Modified HPV16 E7 Genes as DNA 
Vaccine against E7-Containing Oncogenic Cells. Virology. 281:231-238. 
 
97. Frazer, I.H., R. Thomas, J. Zhou, G.R. Leggatt, L. Dunn, N. McMillan, R.W. Tindle, L. 
Filgueira, P. Manders, P. Barnard, M. Sharkey. 1999. Potential strategies utilised by 
papillomavirus to evade host immunity. Immunol Rev. 168:131-42.  
 
98. Merchlinsky, M., and  Moss, B. 1989. Nucleotide sequence required for resolution of the 
concatamer junction of vaccinia virus DNA. J.Virol. 63:4354-4361. 
 
99. Smith, L., and Mausun, L. 2004. The exit of Vaccinia Virus from infected cells. Virus Res. 
106:189-197. 
 
100. Vanderplasschen, A., Hollinshead, M., and Smith, G. L.. 1998. Intracellular and extracellular 
vaccinia virions enter cells by different mechanisms. Journal of General Virology 79:877-887. 
 
101. Alfonso, C., Tulman, E.R., Lu, Z., Zsak, L., Kutish, G.F., Rock, D.L. 2000. The genome of 
fowlpox virus. J Virol. 74:3815-31. 
 
102. De Giuli Morghen, C., Radaelli, A., Zanotto, C., Marconi, P., Manservigi, R. 2000. Virus 
vectors for immunoprophylaxis. AIDS reviews. 2:127-35. 
 
103. Belshe, R.B., Gorse, G.J., Mulligan, M.J., Evans, T.G., Keefer, M.C., Excler, J.L., et al. 1998. 
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 
recombinant vaccines in uninfected volunteers. AIDS. 12:2407-15. 
 
104. Belshe, R.B., Stevens, C., Gorse, G.J., Buchbinder, S.P., Weinhold, K., Sheppard, H., et al. 
2001. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus 
Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J 
Infect Dis. 183:1343-52. 
 
105. Taylor, J., Paoletti, E. 1988. Fowlpox virus as a vector in non-avian species. Vaccine. 6:466-
8. 
 
106. Taylor, J., Weinberg, R., Languet, B., Desmettre, P., Paoletti, E. 1988. Recombinant fowlpox 
virus inducing protective immunity in nonavian species. Vaccine. 6:497-503. 
 
107. Crawford, J.M., Earl, P.L., Moss, B., Reimann, K.A., Wyand, M.S., Manson, K.H., et al. 1999. 
Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J 
Virol. 73:10199-207. 
 
99 
 
108. Leno, M., Buge, S.L., Patterson, L.J., Robert-Guroff, M. 2000. Development of prophylactic 
vaccines against HIV. In: Fuchs D, Aruoma OI, editors.Pharmacology of HIV infection and 
AIDS. 71-104. 
 
109. Paoletti, E. 1996. Applications of pox virus vectors to vaccination: an update. PNAS USA. 
93:11349-53. 
 
110. Arp, J., Rovinski, B., Sambhara, S., Tartaglia, J., Dekaban, G.A. 1999. Human 
Immunodeficiency Virus type 1 envelope-specific cytotoxic T lymphocytes response 
dynamics after prime-boost vaccine regimen with Human Immunodeficiency Virus type 1 
canarypox and pseudovirions. Viral Immunol. 12:281-96. 
 
111. Hodge, J.W., McLaughlin, J.P., Kantor, J.A., Schlom, J. 1997. Diversified prime and boost 
protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus 
to enhance T-cell immunity and antitumor responses. Vaccine. 15:759-68. 
 
112. Mastrangelo, M. J., L. C. Eisenlohr, L. Gomella, and E. C. Lattime. 2000. Poxvirus vectors: 
orphaned and underappreciated. J. Clin. Invest. 105:1031-1034.  
 
113. Zanotto, C., Pozzi, E., Pacchioni, S., Volonté, L., De Giuli Morghen, C., Radaelli, A. 2010. 
Canarypox and fowlpox viruses as recombinant vaccine vectors: a biological and 
immunological comparison. Antiviral Res. 88(1):53-63. 
 
114. Kent, S.J., Zhao, A., Dale, C.J., Land, S., Boyle, D.B., Ramshaw, I.A. 2000. A recombinant 
avipoxvirus HIV-1 vaccine expressing interferon- gamma is safe and immunogenic in 
macaques. Vaccine. 18:2250-6. 
 
115. Hutchings, C.L., Gilbert, S.C., Hill, A.V. and Moore, A.C. 2005. Novel protein and poxvirus-
based vaccine combinations for simultaneous induction of humoral and cell-mediated 
immunity. J.Immunol. 175:599-606. 
 
116. Moss, B. 1996. Genetically engineered poxviruses for recombinant gene expression, 
vaccination, and safety. Proc.Natl.Acad.Sci.USA 93:11341-11348. 
 
117. Fenner, F. 2000. Adventures with poxviruses of vertebrates. FEMS Immunol.Med.Microbiol. 
24:123-133. 
 
118. Merchlinsky, M. and Moss, B. 1992. Introduction of foreign DNA into the vaccinia virus 
genome by in vitro ligation: recombination-independent selectable cloning vectors. Virology 
190:522-526. 
 
119. Pozzi, E., V. Basavecchia, C. Zanotto, S. Pacchioni, C. De Giuli Morghen, and A. Radaelli. 
2009. Construction and characterization of recombinant fowlpox viruses expressing human 
papilloma virus E6 and E7 oncoproteins. J. Virol. Methods 158:184-189. 
 
120.  Radaelli, A., Bonduelle, O., Beggio, P., Mahe, B., Pozzi, E., Elli, V., Paganini, M., Zanotto, C., 
De Giuli Morghen, C., Combadière, B. 2007. Prime-boost immunization with DNA, 
recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-
producing T cells against the HIV-envelope protein in mice that control env-bearing tumour 
cells. Vaccine. 25:2128- 2138. 
100 
 
 
121.  Peng, S., Ji, H., Trimble, C., He, L., Tsai, Y.C., Yeatermeyer, J., Boyd, D.A., Hung, C.F., Wu, 
T.C. 2004. Development of a DNA vaccine targeting human papillomavirus type 16 
oncoprotein E6. J Virol. 78:8468-8476. 
 
122.  Jochmus, I., Osen, W., Altmann, A., Buck, G., Hofmann, B., Schneider, A., Gissmann, L., 
Rammensee, H.G. 1997. Specificity of human cytotoxic T lymphocytes induced by a human 
papillomavirus type 16 E7-derived peptide. J Gen Virol. 78:1689-1695. 
 
123. Feltkamp, M.C., Smits, H.L., Vierboom, M.P., Minnaar, R.P., de Jongh, B.M., Drijfhout, J.W., 
ter Schegget, J., Melief, C.J., Kast, W.M., 1993. Vaccination with cytotoxic T lymphocyte 
epitope-containing peptide protects against a tumor induced by human papillomavirus type 
16-transformed cells. European Journal of Immunology. 23:2242–2249. 
 
124. Hsu, K.F., Hung, C.F., Cheng, W.F., He, L., Slater, L.A., Ling, M., Wu, T.C., 2001. 
Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat 
shock protein 70 to an antigen. Gene Therapy. 8:376–383. 
 
125. Schellenbacher, C., R. Roden, and R. Kirnbauer. 2009. Chimeric L1-L2 virus-like particles as 
potential broad-spectrum human papillomavirus vaccines. J. Virol. 83:10085-10095.  
 
126. Paz De la Rosa,G., A. Monroy-García, M.de L. Mora-García, C.G. Peña, J. Hernández-
Montes, B. Weiss-Steider, M.A. Gómez-Lim. 2009. An HPV 16 L1-based chimeric human 
papilloma virus-like particles containing a string of epitopes produced in  plants is able to 
elicit humoral and cytotoxic T-cell activity in mice. Virol J. 6:2.  
 
127. Androphy, E.J., Hubbert, N.L., Schiller, J.T., Lowy, D.R. 1987. Identification of the HPV-16 E6 
protein from transformed mouse cells and human cervical carcinoma cells. EMBO J. 6:989-
992. 
 
128. Nominé, Y., Charbonnier, S., Ristriani, T., Stier, G., Masson, M., Cavusoglu, N., Van 
Dorsselaer, A., Weiss, E., Kieffer, B., Travé, G. 2003. Domain Substructure of HPV E6 
Oncoprotein: Biophysical Characterization of the E6 C-Terminal DNA Binding Domain. 
Biochemistry. 42:4909-4917. 
 
129. Sedman, S.A., Barbosa, M.S., Vass, W.C., Hubbert, N.L., Haas, J.A., Lowy, D.R., Schiller, 
J.T. 1991. The full-length E6 protein of human papillomavirus type 16 has transforming and 
trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J 
Virol. 65:4860-4866. 
 
130. Massa, S., Franconi, R., Brandi, R., Muller, A., Mett, V., Yusibov, V., Venuti, A. 2007. Anti-
cancer activity of plant-produced HPV16 E7 vaccine. Vaccine. 25:3018–3021. 
 
131. Laurson, J., Raj, K. 2011. Localisation of human papillomavirus 16 E7 oncoprotein changes 
with cell confluence. PLoS One. 6:e21501. 
 
132 Radaelli, A., Pozzi, E., Pacchioni, S., Zanotto, C., De Giuli Morghen, C. 2010. Fowlpox virus 
recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical 
carcinoma elicit humoral and cell-mediated responses in rabbits. J Transl Med. 8:40. 
 
133. Smotkin, D. & Wettstein, F. 1986. Transcription of human papillomavirus type 16 early genes 
in cervical cancer and cancer-derived cell line and identification of the E7 protein. Proc Natl 
Acad Sci USA. 83:4680-4684. 
 
101 
 
134. Mizuuchi, M., Hirohashi, Y., Torigoe, T., Kuroda, T., Yasuda, K., Shimizu, Y., Saito, T., Sato, 
N. 2012. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes 
anti-HPV E6 and E7 CTL responses. Exp Mol Pathol. 92:185-190. 
 
135. Johnston, J.B., McFadden, G. 2003. Poxvirus immunomodulatory strategies: current 
perspectives. Journal of Virology. 77:6093–6100. 
 
136. Kanodia, S., Da Silva, D.M., Kast, W.M. 2008. Recent advances in strategies for 
immunotherapy of human papillomavirus-induced lesions. Int J Cancer. 122:247-259 
 
137. Gissmann, L. 2007. in Modern Uterine Cytopathology, eds. Meisels, A. & Morin, C. (ASCP 
Press, Chicago), pp. 169-200. 
 
138. Meyer, S.I., Fuglsang, K., Blaakaer, J. 2014. Cell-mediated immune response: a clinical 
review of the therapeutic potential of human papillomavirus vaccination. Acta Obstet Gynecol 
Scand. 10.1111/aogs.12480. 
 
139. Peng, S., Song, L., Knoff, J., Wang, J.W., Chang, Y.N., Hannaman, D., Wu, T.C., Alvarez, 
R.D., Roden, R.B., Hung, C.F. 2014. Control of HPV-associated tumors by innovative 
therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci. 4:11. 
 
140. Brandsma, J.L., Shlyankevich, M., Su, Y., Zelterman, D., Rose, J., Buonocore, L. 2010. 
Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked 
DNA and/or vesicular stomatitis virus vectors. Vaccine. 28:8345-8351. 
 
141. Brandsma, J.L., Shlyankevich, M., Zelterman, D., Su, Y. 2014. Therapeutic vaccination of 
rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. Vaccine. 
25:6158-6163. 
 
142. Bagarazzi, M.L., Yan, J., Morrow, M.P., Shen, X., Parker, R.L., Lee, J.C., Giffear, M., 
Pankhong, P., Khan, A.S., Broderick, K.E., Knott, C., Lin, F., Boyer, J.D., Draghia-Akli, R., 
White, C.J., Kim, C.J., Weiner, D.B., Sardesai, N.Y. 2012. Immunotherapy against HPV16/18 
generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med. 4:155ra138. 
 
143. Frazer, I.H., Leggatt, G.R., Mattarollo, S.R. 2011. Prevention and treatment of papillomavirus-
related cancers through immunization. Annual Review of Immunology. 29:111–138. 
 
144. Van der Burg, S.H., Kwappenberg, K.M., O’Neill, T., Brandt, R.M., Melief, C.J., Hickling, J.K., 
Offringa, R. 2001. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 
fusion protein vaccine, in homologous and heterologous primeboost regimens. Vaccine. 
19:3652–3660. 
 
145. Baxby, D., Paoletti, E. 1992. Potential use of nonreplicating vectors as recombinant vaccines. 
Vaccine. 10:8–9. 
 
146. Skinner, M.A., Laidlaw, S.M., Eldaghayes, I., Kaiser, P., Cottingham, M.G. 2005. Fowlpox 
virus as a recombinant vaccine vector for use in mammals and poultry. Expert Review on 
Vaccines. 4:63–76. 
 
